Ignite Creation Date:
2025-12-25 @ 2:11 AM
Ignite Modification Date:
2025-12-26 @ 12:39 AM
Study NCT ID:
NCT03481660
Status:
COMPLETED
Last Update Posted:
2025-01-07
First Post:
2018-03-19
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C000622091', 'term': 'brolucizumab'}, {'id': 'C533178', 'term': 'aflibercept'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'Novartis.email@Novartis.com', 'phone': '862-778-8300', 'title': 'Study Director', 'organization': 'Novartis Pharmaceuticals'}, 'certainAgreement': {'otherDetails': "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.", 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'From first dose of study treatment up to 30 days after last dose (maximum 35 months)', 'description': 'Adverse Events (AEs) and All-cause mortality were collected in the Safety Set', 'eventGroups': [{'id': 'EG000', 'title': 'Brolucizumab 6mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule', 'otherNumAtRisk': 179, 'deathsNumAtRisk': 179, 'otherNumAffected': 131, 'seriousNumAtRisk': 179, 'deathsNumAffected': 13, 'seriousNumAffected': 53}, {'id': 'EG001', 'title': 'Aflibercept 2mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks', 'otherNumAtRisk': 181, 'deathsNumAtRisk': 181, 'otherNumAffected': 134, 'seriousNumAtRisk': 181, 'deathsNumAffected': 9, 'seriousNumAffected': 60}, {'id': 'EG002', 'title': 'Overall', 'description': 'Overall', 'otherNumAtRisk': 360, 'deathsNumAtRisk': 360, 'otherNumAffected': 265, 'seriousNumAtRisk': 360, 'deathsNumAffected': 22, 'seriousNumAffected': 113}], 'otherEvents': [{'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 16}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Blepharitis - Fellow eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 7}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Blepharitis - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 6}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cataract - Fellow eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 16}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 27}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cataract - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 12}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 19}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 31}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Conjunctival haemorrhage - Fellow eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 10}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Conjunctival haemorrhage - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 15}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Diabetic retinal oedema - Fellow eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 18}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 16}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 34}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Diabetic retinopathy - Fellow eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 6}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Dry eye - Fellow eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 16}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Dry eye - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 18}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Eye pain - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 10}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Eye pruritus - Fellow eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 5}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Eye pruritus - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 5}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Macular fibrosis - Fellow eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 6}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Macular oedema - Fellow eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 8}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Vision blurred - Fellow eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 4}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Vision blurred - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 6}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Visual acuity reduced - Fellow eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 7}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Visual acuity reduced - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 12}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Vitreous floaters - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 8}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Vitreous haemorrhage - Fellow eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 11}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Vitreous haemorrhage - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 6}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Abdominal pain upper', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 6}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 10}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 10}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 10}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 5}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Oedema peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 6}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Peripheral swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 4}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 13}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 12}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'COVID-19', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 7}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Conjunctivitis - Fellow eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 6}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Conjunctivitis - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 7}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Herpes zoster', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 7}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 11}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 16}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 17}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 33}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Pulpitis dental', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 6}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Rhinitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 6}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 8}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 9}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Blood creatinine increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 10}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Blood pressure increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 9}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Blood triglycerides increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 8}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Blood urea increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 7}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Glycosylated haemoglobin increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 12}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Intraocular pressure increased - Fellow eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 7}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Intraocular pressure increased - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 10}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Protein urine present', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 9}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'White blood cells urine positive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 5}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Gout', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 8}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Hyperlipidaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 10}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 10}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 9}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 4}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 5}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 12}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Chronic kidney disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 8}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Diabetic nephropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 12}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Proteinuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 13}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 19}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Benign prostatic hyperplasia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 7}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 15}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Diabetic foot', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 7}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 15}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 17}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 32}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Peripheral arterial occlusive disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 6}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}], 'seriousEvents': [{'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Iron deficiency anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Microcytic anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Acute coronary syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Acute myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Angina pectoris', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Aortic valve stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Atrial fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Atrial flutter', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cardiac arrest', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cardiac failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 6}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cardiac failure acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cardiac failure congestive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cardiogenic shock', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cardiopulmonary failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Coronary artery disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 3}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Coronary artery stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 3}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 3}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Myocardial ischaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Vertigo positional', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Goitre', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Glaucoma - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Retinal artery occlusion - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Retinal detachment - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Retinal tear - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Uveitis - Fellow eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Uveitis - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Vitreous haemorrhage - Fellow eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Abdominal pain upper', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Duodenal ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Inguinal hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Pancreatitis acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Rectal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Death', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 3}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Mass', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Oedema peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Sudden death', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cholecystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cholecystitis chronic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cholelithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Anaphylactic reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Immune system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Bone abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'COVID-19', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 7}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'COVID-19 pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cellulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Clostridium difficile colitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Endophthalmitis - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Erysipelas', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Fungal oesophagitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Gangrene', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 5}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Herpes zoster', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Localised infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Ophthalmic herpes zoster - Study eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Orchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Osteomyelitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 7}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Pneumonia viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Pyelonephritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Streptococcal infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Urosepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Femoral neck fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Joint dislocation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Subdural haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Wrist fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Haemoglobin decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Diabetes mellitus inadequate control', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Fluid overload', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Fluid retention', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Gout', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Hypoglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Type 1 diabetes mellitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Intervertebral disc protrusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Osteonecrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Benign oesophageal neoplasm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Biliary neoplasm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Bronchial carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cholangiocarcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Colon adenoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Colon cancer stage I', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Gastric cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Hepatic cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Lung neoplasm malignant', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Malignant neoplasm of unknown primary site', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Metastasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Neoplasm malignant', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Ovarian cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Pleomorphic adenoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Squamous cell carcinoma of lung', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': "Waldenstrom's macroglobulinaemia", 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Arachnoiditis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': "Bickerstaff's encephalitis", 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Carotid artery stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cerebellar haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cerebellar stroke', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cerebrovascular accident', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 4}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Haemorrhagic stroke', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Hemiparesis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Hypoglycaemic coma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Ischaemic stroke', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Transient ischaemic attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Acute kidney injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Chronic kidney disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 3}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Diabetic nephropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 3}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Dysuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Nephropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Nephrotic syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Renal failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Urinary retention', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Breast hypoplasia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Postmenopausal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Asthma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Hypoventilation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Pulmonary embolism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Pulmonary oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Sleep apnoea syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Diabetic foot', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Aortic stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Arterial stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Arteriovenous fistula', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Extremity necrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 2}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Peripheral arterial occlusive disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Peripheral ischaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 179, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 181, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 360, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}], 'frequencyThreshold': '2'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52 for the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '10.6', 'groupId': 'OG000', 'lowerLimit': '9.3', 'upperLimit': '11.9'}, {'value': '9.4', 'groupId': 'OG001', 'lowerLimit': '8.1', 'upperLimit': '10.7'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.2', 'ciLowerLimit': '-0.6', 'ciUpperLimit': '3.1', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.94', 'groupDescription': 'BCVA at Week 52', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'NON_INFERIORITY', 'nonInferiorityComment': '(4-letter margin) (1-sided)'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 52', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Scores on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Average Mean Change From Baseline in BCVA Over the Period Week 40 Through Week 52 for the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '10.3', 'groupId': 'OG000', 'lowerLimit': '9.1', 'upperLimit': '11.5'}, {'value': '9.4', 'groupId': 'OG001', 'lowerLimit': '8.2', 'upperLimit': '10.6'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.9', 'ciLowerLimit': '-0.9', 'ciUpperLimit': '2.6', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.88', 'groupDescription': 'BCVA over period Week 40 through Week 52', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'NON_INFERIORITY', 'nonInferiorityComment': '(4-letter margin) (1-sided)'}, {'pValue': '0.164', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'BCVA over period Week 40 through Week 52', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, period Week 40 through Week 52', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. For each participants, this endpoint was defined as the mean change from baseline to the average value over the period Week 40 through Week 52. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Scores on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': '(Brolucizumab Treatment Arm Only): Percentage of Participants Maintained at q12w up to Week 52 and up to q12w/q16w up to Week 100.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 48', 'categories': [{'measurements': [{'value': '50.3', 'groupId': 'OG000', 'lowerLimit': '42.5', 'upperLimit': '57.7'}]}]}, {'title': 'Week 96', 'categories': [{'measurements': [{'value': '36.8', 'groupId': 'OG000', 'lowerLimit': '29.1', 'upperLimit': '45.5'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 52, Week 100', 'description': 'The number of participants maintaining every 12 weeks (q12w) treatment status in the Brolucizumab arm was derived based on Kaplan-Meier estimates time-to-first q8w treatment need. Positive treatment status was defined as intravitreal treatment (IVT) injections per planned dosing regimen \\[every 12 weeks (q12w)\\].', 'unitOfMeasure': 'Percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Efficacy/Safety approach'}, {'type': 'SECONDARY', 'title': '(Brolucizumab Treatment Arm Only): Percentage of Participants Maintained at q12w up to Week 52 Within Those Patients That Qualified for q12w at Week 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '87', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '95.1', 'groupId': 'OG000', 'lowerLimit': '87.4', 'upperLimit': '98.1'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 36, Week 52', 'description': 'The number of participants maintaining every 12 weeks (q12w) treatment status in the Brolucizumab arm was derived based on Kaplan-Meier estimates time-to-first q8w treatment need. Positive treatment status was defined as intravitreal treatment (IVT) injections per planned dosing regimen \\[every 12 weeks (q12w)\\].', 'unitOfMeasure': 'Percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Efficacy/Safety approach'}, {'type': 'SECONDARY', 'title': '(Brolucizumab Treatment Arm Only): Percentage of Participants Maintained at q12w/q16w up to Week 100, Within Those Patients That Qualified for q12w at Week 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '87', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '69.6', 'groupId': 'OG000', 'lowerLimit': '57.4', 'upperLimit': '78.9'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 36, Week 100', 'description': 'Disease activity assessments (DAAs) were performed to identify q8w-need at pre-specified visits (Weeks 32, 36, 48, 60, 72 and every visit from Week 72 through Week 96). Weeks 32 and 36 were the two DAA visits of the initial q12w cycle after the loading phase of the brolucizumab arm. At Week 72 or Week 76 (if DAA/disease stability assessment was missed at Week 72), participants in the brolucizumab were evaluated for an additional 4-week dose regimen extension.\n\nThe number of participants maintaining every 12 weeks (q12w) treatment status in the Brolucizumab arm was derived based on Kaplan-Meier estimates time-to-first q8w treatment need. Positive treatment status was defined as intravitreal treatment (IVT) injections per planned dosing regimen \\[every 12 weeks (q12w)\\].', 'unitOfMeasure': 'Percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Efficacy/Safety approach'}, {'type': 'SECONDARY', 'title': '(Brolucizumab Treatment Arm Only): Percentage of Participants Maintained on q16w up to Week 100 Within the Patients on q12w at Week 68 and on q16w at Week 76', 'denoms': [{'units': 'Participants', 'counts': [{'value': '44', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '87.9', 'groupId': 'OG000', 'lowerLimit': '73.3', 'upperLimit': '94.8'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 68, Week 76, Week 100', 'description': 'Disease activity assessments (DAAs) were performed to identify q8w-need at pre-specified visits (Weeks 32, 36, 48, 60, 72 and every visit from Week 72 through Week 96). Weeks 32 and 36 were the two DAA visits of the initial q12w cycle after the loading phase of the brolucizumab arm. At Week 72 or Week 76 (if DAA/disease stability assessment was missed at Week 72), participants in the brolucizumab were evaluated for an additional 4-week dose regimen extension.\n\nThe number of participants maintaining every 12 weeks (q12w) treatment status in the Brolucizumab arm was derived based on Kaplan-Meier estimates time-to-first q8w treatment need. Positive treatment status was defined as intravitreal treatment (IVT) injections per planned dosing regimen \\[every 12 weeks (q12w)\\].', 'unitOfMeasure': 'Percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Efficacy/Safety approach'}, {'type': 'SECONDARY', 'title': '(Brolucizumab Treatment Arm Only): Percentage of Participants Re-assigned and Maintained on q12w up to Week 100 Within the Patients on q8w at Week 68 and on q12w at Week 80', 'denoms': [{'units': 'Participants', 'counts': [{'value': '34', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '73.1', 'groupId': 'OG000', 'lowerLimit': '54.5', 'upperLimit': '85.0'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 68, Week 80, Week 100', 'description': 'Disease activity assessments (DAAs) were performed to identify q8w-need at pre-specified visits (Weeks 32, 36, 48, 60, 72 and every visit from Week 72 through Week 96). Weeks 32 and 36 were the two DAA visits of the initial q12w cycle after the loading phase of the brolucizumab arm. At Week 72 or Week 76 (if DAA/disease stability assessment was missed at Week 72), participants in the brolucizumab were evaluated for an additional 4-week dose regimen extension.\n\nThe number of participants maintaining every 12 weeks (q12w) treatment status in the Brolucizumab arm was derived based on Kaplan-Meier estimates time-to-first q8w treatment need. Positive treatment status was defined as intravitreal treatment (IVT) injections per planned dosing regimen \\[every 12 weeks (q12w)\\].', 'unitOfMeasure': 'Percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Efficacy/Safety approach'}, {'type': 'SECONDARY', 'title': '(Brolucizumab Treatment Arm Only): Number of Participants With Injections Per Planned Dosing Regimen (Every 8, 12 or 16 Weeks)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '141', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'categories': [{'title': 'q8w', 'measurements': [{'value': '74', 'groupId': 'OG000'}]}, {'title': 'q12w', 'measurements': [{'value': '32', 'groupId': 'OG000'}]}, {'title': 'q16w', 'measurements': [{'value': '35', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Week 100', 'description': 'Reported categorically for the subjects who completed the study treatment period: every 8 weeks (q8w), Every 12 weeks (q12w), Every 16 weeks (q16w)', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set. Only participants who completed the study treatment period were included in the analysis.'}, {'type': 'SECONDARY', 'title': 'Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Each Visit up to Week 100 for the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '5.1', 'groupId': 'OG000', 'lowerLimit': '4.3', 'upperLimit': '6.0'}, {'value': '4.2', 'groupId': 'OG001', 'lowerLimit': '3.4', 'upperLimit': '5.1'}]}]}, {'title': 'Week 6', 'categories': [{'measurements': [{'value': '6.8', 'groupId': 'OG000', 'lowerLimit': '5.9', 'upperLimit': '7.6'}, {'value': '5.9', 'groupId': 'OG001', 'lowerLimit': '5.0', 'upperLimit': '6.7'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '7.8', 'groupId': 'OG000', 'lowerLimit': '6.9', 'upperLimit': '8.7'}, {'value': '6.7', 'groupId': 'OG001', 'lowerLimit': '5.8', 'upperLimit': '7.5'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '8.6', 'groupId': 'OG000', 'lowerLimit': '7.6', 'upperLimit': '9.5'}, {'value': '7.7', 'groupId': 'OG001', 'lowerLimit': '6.7', 'upperLimit': '8.6'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '9.0', 'groupId': 'OG000', 'lowerLimit': '7.9', 'upperLimit': '10.1'}, {'value': '8.3', 'groupId': 'OG001', 'lowerLimit': '7.2', 'upperLimit': '9.5'}]}]}, {'title': 'Week 18', 'categories': [{'measurements': [{'value': '9.2', 'groupId': 'OG000', 'lowerLimit': '8.0', 'upperLimit': '10.3'}, {'value': '9.2', 'groupId': 'OG001', 'lowerLimit': '8.0', 'upperLimit': '10.3'}]}]}, {'title': 'Week 20', 'categories': [{'measurements': [{'value': '9.6', 'groupId': 'OG000', 'lowerLimit': '8.4', 'upperLimit': '10.8'}, {'value': '9.4', 'groupId': 'OG001', 'lowerLimit': '8.2', 'upperLimit': '10.6'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'value': '10.0', 'groupId': 'OG000', 'lowerLimit': '8.8', 'upperLimit': '11.2'}, {'value': '8.7', 'groupId': 'OG001', 'lowerLimit': '7.5', 'upperLimit': '9.9'}]}]}, {'title': 'Week 28', 'categories': [{'measurements': [{'value': '9.8', 'groupId': 'OG000', 'lowerLimit': '8.6', 'upperLimit': '11.1'}, {'value': '9.4', 'groupId': 'OG001', 'lowerLimit': '8.2', 'upperLimit': '10.6'}]}]}, {'title': 'Week 32', 'categories': [{'measurements': [{'value': '10.3', 'groupId': 'OG000', 'lowerLimit': '9.1', 'upperLimit': '11.5'}, {'value': '8.9', 'groupId': 'OG001', 'lowerLimit': '7.7', 'upperLimit': '10.1'}]}]}, {'title': 'Week 36', 'categories': [{'measurements': [{'value': '9.6', 'groupId': 'OG000', 'lowerLimit': '8.4', 'upperLimit': '10.9'}, {'value': '9.4', 'groupId': 'OG001', 'lowerLimit': '8.2', 'upperLimit': '10.7'}]}]}, {'title': 'Week 40', 'categories': [{'measurements': [{'value': '9.9', 'groupId': 'OG000', 'lowerLimit': '8.7', 'upperLimit': '11.2'}, {'value': '9.2', 'groupId': 'OG001', 'lowerLimit': '7.9', 'upperLimit': '10.4'}]}]}, {'title': 'Week 44', 'categories': [{'measurements': [{'value': '10.6', 'groupId': 'OG000', 'lowerLimit': '9.3', 'upperLimit': '11.8'}, {'value': '9.5', 'groupId': 'OG001', 'lowerLimit': '8.3', 'upperLimit': '10.8'}]}]}, {'title': 'Week 48', 'categories': [{'measurements': [{'value': '10.1', 'groupId': 'OG000', 'lowerLimit': '8.8', 'upperLimit': '11.3'}, {'value': '9.6', 'groupId': 'OG001', 'lowerLimit': '8.3', 'upperLimit': '10.9'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'value': '10.6', 'groupId': 'OG000', 'lowerLimit': '9.3', 'upperLimit': '11.9'}, {'value': '9.4', 'groupId': 'OG001', 'lowerLimit': '8.1', 'upperLimit': '10.7'}]}]}, {'title': 'Week 56', 'categories': [{'measurements': [{'value': '10.7', 'groupId': 'OG000', 'lowerLimit': '9.3', 'upperLimit': '12.0'}, {'value': '9.5', 'groupId': 'OG001', 'lowerLimit': '8.2', 'upperLimit': '10.9'}]}]}, {'title': 'Week 60', 'categories': [{'measurements': [{'value': '10.5', 'groupId': 'OG000', 'lowerLimit': '9.1', 'upperLimit': '11.9'}, {'value': '9.3', 'groupId': 'OG001', 'lowerLimit': '8.0', 'upperLimit': '10.7'}]}]}, {'title': 'Week 64', 'categories': [{'measurements': [{'value': '11.0', 'groupId': 'OG000', 'lowerLimit': '9.7', 'upperLimit': '12.3'}, {'value': '9.5', 'groupId': 'OG001', 'lowerLimit': '8.2', 'upperLimit': '10.8'}]}]}, {'title': 'Week 68', 'categories': [{'measurements': [{'value': '11.0', 'groupId': 'OG000', 'lowerLimit': '9.6', 'upperLimit': '12.3'}, {'value': '9.5', 'groupId': 'OG001', 'lowerLimit': '8.2', 'upperLimit': '10.8'}]}]}, {'title': 'Week 72', 'categories': [{'measurements': [{'value': '11.0', 'groupId': 'OG000', 'lowerLimit': '9.6', 'upperLimit': '12.3'}, {'value': '9.4', 'groupId': 'OG001', 'lowerLimit': '8.1', 'upperLimit': '10.8'}]}]}, {'title': 'Week 76', 'categories': [{'measurements': [{'value': '10.5', 'groupId': 'OG000', 'lowerLimit': '9.2', 'upperLimit': '11.8'}, {'value': '9.8', 'groupId': 'OG001', 'lowerLimit': '8.4', 'upperLimit': '11.1'}]}]}, {'title': 'Week 80', 'categories': [{'measurements': [{'value': '10.2', 'groupId': 'OG000', 'lowerLimit': '8.9', 'upperLimit': '11.6'}, {'value': '9.4', 'groupId': 'OG001', 'lowerLimit': '8.1', 'upperLimit': '10.8'}]}]}, {'title': 'Week 84', 'categories': [{'measurements': [{'value': '10.9', 'groupId': 'OG000', 'lowerLimit': '9.4', 'upperLimit': '12.4'}, {'value': '8.9', 'groupId': 'OG001', 'lowerLimit': '7.4', 'upperLimit': '10.4'}]}]}, {'title': 'Week 88', 'categories': [{'measurements': [{'value': '10.7', 'groupId': 'OG000', 'lowerLimit': '9.1', 'upperLimit': '12.4'}, {'value': '8.6', 'groupId': 'OG001', 'lowerLimit': '7.0', 'upperLimit': '10.2'}]}]}, {'title': 'Week 92', 'categories': [{'measurements': [{'value': '10.7', 'groupId': 'OG000', 'lowerLimit': '9.1', 'upperLimit': '12.2'}, {'value': '9.3', 'groupId': 'OG001', 'lowerLimit': '7.7', 'upperLimit': '10.8'}]}]}, {'title': 'Week 96', 'categories': [{'measurements': [{'value': '10.7', 'groupId': 'OG000', 'lowerLimit': '9.1', 'upperLimit': '12.3'}, {'value': '8.5', 'groupId': 'OG001', 'lowerLimit': '6.8', 'upperLimit': '10.1'}]}]}, {'title': 'Week 100', 'categories': [{'measurements': [{'value': '10.9', 'groupId': 'OG000', 'lowerLimit': '9.3', 'upperLimit': '12.6'}, {'value': '8.4', 'groupId': 'OG001', 'lowerLimit': '6.7', 'upperLimit': '10.1'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'LS mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.2', 'ciLowerLimit': '-0.6', 'ciUpperLimit': '3.1', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.94', 'groupDescription': 'BCVA at Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment Difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'LS mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.6', 'ciLowerLimit': '0.2', 'ciUpperLimit': '4.9', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.21', 'groupDescription': 'BCVA at Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment Difference'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Scores on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Average Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Over the Period Week 4 to Week 52/100 for the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'period Week 4 through Week 52', 'categories': [{'measurements': [{'value': '9.1', 'groupId': 'OG000', 'lowerLimit': '8.2', 'upperLimit': '10.1'}, {'value': '8.4', 'groupId': 'OG001', 'lowerLimit': '7.4', 'upperLimit': '9.3'}]}]}, {'title': 'period Week 4 through Week 100', 'categories': [{'measurements': [{'value': '9.8', 'groupId': 'OG000', 'lowerLimit': '8.8', 'upperLimit': '10.9'}, {'value': '8.7', 'groupId': 'OG001', 'lowerLimit': '7.7', 'upperLimit': '9.8'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'LS mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.8', 'ciLowerLimit': '-0.6', 'ciUpperLimit': '2.1', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.70', 'groupDescription': 'BCVA over period Week 4 through Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'LS mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.1', 'ciLowerLimit': '-0.4', 'ciUpperLimit': '2.6', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.78', 'groupDescription': 'BCVA over period Week 4 through Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, period Week 4 through Week 52, period Week 4 through Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. For each participants, this endpoint was defined as the mean change from baseline to the average value over the periods: Week 4 through Week 52, Week 4 through Week 100. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Scores on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Average Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Over the Period Week 20 to Week 52/100 and Week 28 to Week 52/100 for the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'period Week 20 through Week 52', 'categories': [{'measurements': [{'value': '10.1', 'groupId': 'OG000', 'lowerLimit': '8.9', 'upperLimit': '11.2'}, {'value': '9.3', 'groupId': 'OG001', 'lowerLimit': '8.1', 'upperLimit': '10.4'}]}]}, {'title': 'period Week 20 through Week 100', 'categories': [{'measurements': [{'value': '10.4', 'groupId': 'OG000', 'lowerLimit': '9.2', 'upperLimit': '11.7'}, {'value': '9.2', 'groupId': 'OG001', 'lowerLimit': '8.0', 'upperLimit': '10.4'}]}]}, {'title': 'period Week 28 through Week 52', 'categories': [{'measurements': [{'value': '10.1', 'groupId': 'OG000', 'lowerLimit': '9.0', 'upperLimit': '11.3'}, {'value': '9.4', 'groupId': 'OG001', 'lowerLimit': '8.2', 'upperLimit': '10.5'}]}]}, {'title': 'period Week 28 through Week 100', 'categories': [{'measurements': [{'value': '10.5', 'groupId': 'OG000', 'lowerLimit': '9.3', 'upperLimit': '11.7'}, {'value': '9.2', 'groupId': 'OG001', 'lowerLimit': '8.0', 'upperLimit': '10.5'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'LS mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.8', 'ciLowerLimit': '-0.9', 'ciUpperLimit': '2.4', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.83', 'groupDescription': 'BCVA over period Week 20 through Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'LS mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.8', 'ciLowerLimit': '-0.9', 'ciUpperLimit': '2.5', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.85', 'groupDescription': 'BCVA over period Week 28 through Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'LS mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.2', 'ciLowerLimit': '-0.5', 'ciUpperLimit': '2.9', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.87', 'groupDescription': 'BCVA over period Week 20 through Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'LS mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.3', 'ciLowerLimit': '-0.5', 'ciUpperLimit': '3.0', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.89', 'groupDescription': 'BCVA over period Week 28 through Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, period Week 20 through Week 52, period Week 20 through Week 100, period Week 28 through Week 52, period Week 28 through Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. For each participants, this endpoint was defined as the mean change from baseline to the average value over the periods: Week 20 through Week 52, Week 20 through Week 100, Week 28 through Week 52, Week 28 through Week 100. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Scores on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Average Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Over the Period Week 88 to 100 for the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '10.8', 'groupId': 'OG000', 'lowerLimit': '9.2', 'upperLimit': '12.3'}, {'value': '8.7', 'groupId': 'OG001', 'lowerLimit': '7.1', 'upperLimit': '10.2'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'LS mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.1', 'ciLowerLimit': '-0.1', 'ciUpperLimit': '4.3', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.12', 'groupDescription': 'BCVA over period Week 88 through Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, period Week 88 through Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. For each participants, this endpoint was defined as the mean change from baseline to the average value over the period Week 88 through Week 100. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Scores on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Gained >= 5 Letters in BCVA From Baseline or Reached BCVA >= 84 Letters at Each Post-baseline Visit for the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '49.2', 'groupId': 'OG000', 'lowerLimit': '41.6', 'upperLimit': '56.7'}, {'value': '46.4', 'groupId': 'OG001', 'lowerLimit': '39.0', 'upperLimit': '54.0'}]}]}, {'title': 'Week 6', 'categories': [{'measurements': [{'value': '62.0', 'groupId': 'OG000', 'lowerLimit': '54.5', 'upperLimit': '69.1'}, {'value': '62.4', 'groupId': 'OG001', 'lowerLimit': '54.9', 'upperLimit': '69.5'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '67.6', 'groupId': 'OG000', 'lowerLimit': '60.2', 'upperLimit': '74.4'}, {'value': '63.5', 'groupId': 'OG001', 'lowerLimit': '56.1', 'upperLimit': '70.5'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '70.9', 'groupId': 'OG000', 'lowerLimit': '63.7', 'upperLimit': '77.5'}, {'value': '73.5', 'groupId': 'OG001', 'lowerLimit': '66.4', 'upperLimit': '79.8'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '71.5', 'groupId': 'OG000', 'lowerLimit': '64.3', 'upperLimit': '78.0'}, {'value': '73.5', 'groupId': 'OG001', 'lowerLimit': '66.4', 'upperLimit': '79.8'}]}]}, {'title': 'Week 18', 'categories': [{'measurements': [{'value': '77.7', 'groupId': 'OG000', 'lowerLimit': '70.8', 'upperLimit': '83.5'}, {'value': '77.9', 'groupId': 'OG001', 'lowerLimit': '71.1', 'upperLimit': '83.7'}]}]}, {'title': 'Week 20', 'categories': [{'measurements': [{'value': '79.3', 'groupId': 'OG000', 'lowerLimit': '72.7', 'upperLimit': '85.0'}, {'value': '76.2', 'groupId': 'OG001', 'lowerLimit': '69.4', 'upperLimit': '82.2'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'value': '79.9', 'groupId': 'OG000', 'lowerLimit': '73.3', 'upperLimit': '85.5'}, {'value': '77.9', 'groupId': 'OG001', 'lowerLimit': '71.1', 'upperLimit': '83.7'}]}]}, {'title': 'Week 28', 'categories': [{'measurements': [{'value': '75.4', 'groupId': 'OG000', 'lowerLimit': '68.4', 'upperLimit': '81.5'}, {'value': '77.9', 'groupId': 'OG001', 'lowerLimit': '71.1', 'upperLimit': '83.7'}]}]}, {'title': 'Week 32', 'categories': [{'measurements': [{'value': '77.1', 'groupId': 'OG000', 'lowerLimit': '70.2', 'upperLimit': '83.0'}, {'value': '80.7', 'groupId': 'OG001', 'lowerLimit': '74.1', 'upperLimit': '86.1'}]}]}, {'title': 'Week 36', 'categories': [{'measurements': [{'value': '74.3', 'groupId': 'OG000', 'lowerLimit': '67.2', 'upperLimit': '80.5'}, {'value': '80.7', 'groupId': 'OG001', 'lowerLimit': '74.1', 'upperLimit': '86.1'}]}]}, {'title': 'Week 40', 'categories': [{'measurements': [{'value': '74.9', 'groupId': 'OG000', 'lowerLimit': '67.8', 'upperLimit': '81.0'}, {'value': '79.6', 'groupId': 'OG001', 'lowerLimit': '72.9', 'upperLimit': '85.2'}]}]}, {'title': 'Week 44', 'categories': [{'measurements': [{'value': '74.3', 'groupId': 'OG000', 'lowerLimit': '67.2', 'upperLimit': '80.5'}, {'value': '80.7', 'groupId': 'OG001', 'lowerLimit': '74.1', 'upperLimit': '86.1'}]}]}, {'title': 'Week 48', 'categories': [{'measurements': [{'value': '76.0', 'groupId': 'OG000', 'lowerLimit': '69.0', 'upperLimit': '82.0'}, {'value': '79.0', 'groupId': 'OG001', 'lowerLimit': '72.3', 'upperLimit': '84.7'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'value': '77.7', 'groupId': 'OG000', 'lowerLimit': '70.8', 'upperLimit': '83.5'}, {'value': '79.0', 'groupId': 'OG001', 'lowerLimit': '72.3', 'upperLimit': '84.7'}]}]}, {'title': 'Week 56', 'categories': [{'measurements': [{'value': '77.7', 'groupId': 'OG000', 'lowerLimit': '70.8', 'upperLimit': '83.5'}, {'value': '80.7', 'groupId': 'OG001', 'lowerLimit': '74.1', 'upperLimit': '86.1'}]}]}, {'title': 'Week 60', 'categories': [{'measurements': [{'value': '76.0', 'groupId': 'OG000', 'lowerLimit': '69.0', 'upperLimit': '82.0'}, {'value': '79.0', 'groupId': 'OG001', 'lowerLimit': '72.3', 'upperLimit': '84.7'}]}]}, {'title': 'Week 64', 'categories': [{'measurements': [{'value': '78.2', 'groupId': 'OG000', 'lowerLimit': '71.4', 'upperLimit': '84.0'}, {'value': '79.0', 'groupId': 'OG001', 'lowerLimit': '72.3', 'upperLimit': '84.7'}]}]}, {'title': 'Week 68', 'categories': [{'measurements': [{'value': '77.7', 'groupId': 'OG000', 'lowerLimit': '70.8', 'upperLimit': '83.5'}, {'value': '76.8', 'groupId': 'OG001', 'lowerLimit': '70.0', 'upperLimit': '82.7'}]}]}, {'title': 'Week 72', 'categories': [{'measurements': [{'value': '79.9', 'groupId': 'OG000', 'lowerLimit': '73.3', 'upperLimit': '85.5'}, {'value': '77.3', 'groupId': 'OG001', 'lowerLimit': '70.6', 'upperLimit': '83.2'}]}]}, {'title': 'Week 76', 'categories': [{'measurements': [{'value': '74.3', 'groupId': 'OG000', 'lowerLimit': '67.2', 'upperLimit': '80.5'}, {'value': '77.3', 'groupId': 'OG001', 'lowerLimit': '70.6', 'upperLimit': '83.2'}]}]}, {'title': 'Week 80', 'categories': [{'measurements': [{'value': '74.3', 'groupId': 'OG000', 'lowerLimit': '67.2', 'upperLimit': '80.5'}, {'value': '75.7', 'groupId': 'OG001', 'lowerLimit': '68.8', 'upperLimit': '81.7'}]}]}, {'title': 'Week 84', 'categories': [{'measurements': [{'value': '78.2', 'groupId': 'OG000', 'lowerLimit': '71.4', 'upperLimit': '84.0'}, {'value': '73.5', 'groupId': 'OG001', 'lowerLimit': '66.4', 'upperLimit': '79.8'}]}]}, {'title': 'Week 88', 'categories': [{'measurements': [{'value': '77.7', 'groupId': 'OG000', 'lowerLimit': '70.8', 'upperLimit': '83.5'}, {'value': '75.7', 'groupId': 'OG001', 'lowerLimit': '68.8', 'upperLimit': '81.7'}]}]}, {'title': 'Week 92', 'categories': [{'measurements': [{'value': '79.3', 'groupId': 'OG000', 'lowerLimit': '72.7', 'upperLimit': '85.0'}, {'value': '74.0', 'groupId': 'OG001', 'lowerLimit': '67.0', 'upperLimit': '80.3'}]}]}, {'title': 'Week 96', 'categories': [{'measurements': [{'value': '78.8', 'groupId': 'OG000', 'lowerLimit': '72.0', 'upperLimit': '84.5'}, {'value': '73.5', 'groupId': 'OG001', 'lowerLimit': '66.4', 'upperLimit': '79.8'}]}]}, {'title': 'Week 100', 'categories': [{'measurements': [{'value': '77.1', 'groupId': 'OG000', 'lowerLimit': '70.2', 'upperLimit': '83.0'}, {'value': '73.5', 'groupId': 'OG001', 'lowerLimit': '66.4', 'upperLimit': '79.8'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.4', 'ciLowerLimit': '-7.6', 'ciUpperLimit': '8.9', 'groupDescription': 'Gain of \\>= 5 letters in BCVA at Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.4', 'ciLowerLimit': '-3.9', 'ciUpperLimit': '14.5', 'groupDescription': 'Gain of \\>= 5 letters in BCVA at Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Gained >= 10 Letters in BCVA From Baseline or Reached BCVA >= 84 Letters at Each Post-baseline Visit for the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '22.9', 'groupId': 'OG000', 'lowerLimit': '17.0', 'upperLimit': '29.8'}, {'value': '23.8', 'groupId': 'OG001', 'lowerLimit': '17.8', 'upperLimit': '30.6'}]}]}, {'title': 'Week 6', 'categories': [{'measurements': [{'value': '34.6', 'groupId': 'OG000', 'lowerLimit': '27.7', 'upperLimit': '42.1'}, {'value': '31.5', 'groupId': 'OG001', 'lowerLimit': '24.8', 'upperLimit': '38.8'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '39.7', 'groupId': 'OG000', 'lowerLimit': '32.4', 'upperLimit': '47.2'}, {'value': '36.5', 'groupId': 'OG001', 'lowerLimit': '29.5', 'upperLimit': '43.9'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '43.0', 'groupId': 'OG000', 'lowerLimit': '35.7', 'upperLimit': '50.6'}, {'value': '45.9', 'groupId': 'OG001', 'lowerLimit': '39.4', 'upperLimit': '53.4'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '44.1', 'groupId': 'OG000', 'lowerLimit': '36.7', 'upperLimit': '51.7'}, {'value': '49.7', 'groupId': 'OG001', 'lowerLimit': '42.2', 'upperLimit': '57.2'}]}]}, {'title': 'Week 18', 'categories': [{'measurements': [{'value': '47.5', 'groupId': 'OG000', 'lowerLimit': '40.0', 'upperLimit': '55.1'}, {'value': '53.0', 'groupId': 'OG001', 'lowerLimit': '45.5', 'upperLimit': '60.5'}]}]}, {'title': 'Week 20', 'categories': [{'measurements': [{'value': '53.1', 'groupId': 'OG000', 'lowerLimit': '45.5', 'upperLimit': '60.6'}, {'value': '56.9', 'groupId': 'OG001', 'lowerLimit': '49.4', 'upperLimit': '64.2'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'value': '56.4', 'groupId': 'OG000', 'lowerLimit': '48.8', 'upperLimit': '63.8'}, {'value': '53.6', 'groupId': 'OG001', 'lowerLimit': '46.0', 'upperLimit': '61.0'}]}]}, {'title': 'Week 28', 'categories': [{'measurements': [{'value': '55.3', 'groupId': 'OG000', 'lowerLimit': '47.7', 'upperLimit': '62.7'}, {'value': '55.2', 'groupId': 'OG001', 'lowerLimit': '47.7', 'upperLimit': '62.6'}]}]}, {'title': 'Week 32', 'categories': [{'measurements': [{'value': '58.7', 'groupId': 'OG000', 'lowerLimit': '51.1', 'upperLimit': '66.0'}, {'value': '51.9', 'groupId': 'OG001', 'lowerLimit': '44.4', 'upperLimit': '59.4'}]}]}, {'title': 'Week 36', 'categories': [{'measurements': [{'value': '57.5', 'groupId': 'OG000', 'lowerLimit': '49.9', 'upperLimit': '64.9'}, {'value': '55.2', 'groupId': 'OG001', 'lowerLimit': '47.7', 'upperLimit': '62.6'}]}]}, {'title': 'Week 40', 'categories': [{'measurements': [{'value': '58.1', 'groupId': 'OG000', 'lowerLimit': '50.5', 'upperLimit': '65.4'}, {'value': '52.5', 'groupId': 'OG001', 'lowerLimit': '44.9', 'upperLimit': '59.9'}]}]}, {'title': 'Week 44', 'categories': [{'measurements': [{'value': '61.5', 'groupId': 'OG000', 'lowerLimit': '53.9', 'upperLimit': '68.6'}, {'value': '56.9', 'groupId': 'OG001', 'lowerLimit': '49.4', 'upperLimit': '64.2'}]}]}, {'title': 'Week 48', 'categories': [{'measurements': [{'value': '60.9', 'groupId': 'OG000', 'lowerLimit': '53.3', 'upperLimit': '68.1'}, {'value': '53.0', 'groupId': 'OG001', 'lowerLimit': '45.5', 'upperLimit': '60.5'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'value': '61.5', 'groupId': 'OG000', 'lowerLimit': '53.9', 'upperLimit': '68.6'}, {'value': '58.6', 'groupId': 'OG001', 'lowerLimit': '51.0', 'upperLimit': '65.8'}]}]}, {'title': 'Week 56', 'categories': [{'measurements': [{'value': '62.0', 'groupId': 'OG000', 'lowerLimit': '54.5', 'upperLimit': '69.1'}, {'value': '54.1', 'groupId': 'OG001', 'lowerLimit': '46.6', 'upperLimit': '61.6'}]}]}, {'title': 'Week 60', 'categories': [{'measurements': [{'value': '61.5', 'groupId': 'OG000', 'lowerLimit': '53.9', 'upperLimit': '68.6'}, {'value': '54.7', 'groupId': 'OG001', 'lowerLimit': '47.1', 'upperLimit': '62.1'}]}]}, {'title': 'Week 64', 'categories': [{'measurements': [{'value': '63.7', 'groupId': 'OG000', 'lowerLimit': '56.2', 'upperLimit': '70.7'}, {'value': '56.9', 'groupId': 'OG001', 'lowerLimit': '49.4', 'upperLimit': '64.2'}]}]}, {'title': 'Week 68', 'categories': [{'measurements': [{'value': '62.0', 'groupId': 'OG000', 'lowerLimit': '54.5', 'upperLimit': '69.1'}, {'value': '57.5', 'groupId': 'OG001', 'lowerLimit': '49.9', 'upperLimit': '64.8'}]}]}, {'title': 'Week 72', 'categories': [{'measurements': [{'value': '63.7', 'groupId': 'OG000', 'lowerLimit': '56.2', 'upperLimit': '70.7'}, {'value': '56.4', 'groupId': 'OG001', 'lowerLimit': '48.8', 'upperLimit': '63.7'}]}]}, {'title': 'Week 76', 'categories': [{'measurements': [{'value': '60.9', 'groupId': 'OG000', 'lowerLimit': '53.3', 'upperLimit': '68.1'}, {'value': '56.9', 'groupId': 'OG001', 'lowerLimit': '49.4', 'upperLimit': '64.2'}]}]}, {'title': 'Week 80', 'categories': [{'measurements': [{'value': '57.5', 'groupId': 'OG000', 'lowerLimit': '49.9', 'upperLimit': '64.9'}, {'value': '55.8', 'groupId': 'OG001', 'lowerLimit': '48.2', 'upperLimit': '63.2'}]}]}, {'title': 'Week 84', 'categories': [{'measurements': [{'value': '63.7', 'groupId': 'OG000', 'lowerLimit': '56.2', 'upperLimit': '70.7'}, {'value': '58.6', 'groupId': 'OG001', 'lowerLimit': '51.0', 'upperLimit': '65.8'}]}]}, {'title': 'Week 88', 'categories': [{'measurements': [{'value': '61.5', 'groupId': 'OG000', 'lowerLimit': '53.9', 'upperLimit': '68.6'}, {'value': '58.0', 'groupId': 'OG001', 'lowerLimit': '50.5', 'upperLimit': '65.3'}]}]}, {'title': 'Week 92', 'categories': [{'measurements': [{'value': '63.7', 'groupId': 'OG000', 'lowerLimit': '56.2', 'upperLimit': '70.7'}, {'value': '58.6', 'groupId': 'OG001', 'lowerLimit': '51.0', 'upperLimit': '65.8'}]}]}, {'title': 'Week 96', 'categories': [{'measurements': [{'value': '62.6', 'groupId': 'OG000', 'lowerLimit': '55.0', 'upperLimit': '69.7'}, {'value': '56.9', 'groupId': 'OG001', 'lowerLimit': '49.4', 'upperLimit': '64.2'}]}]}, {'title': 'Week 100', 'categories': [{'measurements': [{'value': '61.5', 'groupId': 'OG000', 'lowerLimit': '53.9', 'upperLimit': '68.6'}, {'value': '54.1', 'groupId': 'OG001', 'lowerLimit': '46.6', 'upperLimit': '61.6'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.4', 'ciLowerLimit': '-3.9', 'ciUpperLimit': '14.7', 'groupDescription': 'Gain of \\>= 10 letters in BCVA at Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '9.9', 'ciLowerLimit': '-0.4', 'ciUpperLimit': '19.4', 'groupDescription': 'Gain of \\>= 10 letters in BCVA at Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Gained >= 15 Letters in BCVA From Baseline or Reached BCVA >= 84 Letters at Each Post-baseline Visit for the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '12.3', 'groupId': 'OG000', 'lowerLimit': '7.9', 'upperLimit': '18.0'}, {'value': '9.4', 'groupId': 'OG001', 'lowerLimit': '5.6', 'upperLimit': '14.6'}]}]}, {'title': 'Week 6', 'categories': [{'measurements': [{'value': '13.4', 'groupId': 'OG000', 'lowerLimit': '8.8', 'upperLimit': '19.3'}, {'value': '13.8', 'groupId': 'OG001', 'lowerLimit': '9.1', 'upperLimit': '19.7'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '25.1', 'groupId': 'OG000', 'lowerLimit': '19.0', 'upperLimit': '32.2'}, {'value': '16.0', 'groupId': 'OG001', 'lowerLimit': '11.0', 'upperLimit': '22.2'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '25.1', 'groupId': 'OG000', 'lowerLimit': '19.0', 'upperLimit': '32.2'}, {'value': '22.1', 'groupId': 'OG001', 'lowerLimit': '16.3', 'upperLimit': '28.9'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '33.5', 'groupId': 'OG000', 'lowerLimit': '26.7', 'upperLimit': '40.9'}, {'value': '25.4', 'groupId': 'OG001', 'lowerLimit': '19.2', 'upperLimit': '32.4'}]}]}, {'title': 'Week 18', 'categories': [{'measurements': [{'value': '31.8', 'groupId': 'OG000', 'lowerLimit': '25.1', 'upperLimit': '39.2'}, {'value': '33.1', 'groupId': 'OG001', 'lowerLimit': '26.3', 'upperLimit': '40.5'}]}]}, {'title': 'Week 20', 'categories': [{'measurements': [{'value': '34.6', 'groupId': 'OG000', 'lowerLimit': '27.7', 'upperLimit': '42.1'}, {'value': '32.6', 'groupId': 'OG001', 'lowerLimit': '25.8', 'upperLimit': '39.9'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'value': '41.9', 'groupId': 'OG000', 'lowerLimit': '34.6', 'upperLimit': '49.5'}, {'value': '30.9', 'groupId': 'OG001', 'lowerLimit': '24.3', 'upperLimit': '38.2'}]}]}, {'title': 'Week 28', 'categories': [{'measurements': [{'value': '40.2', 'groupId': 'OG000', 'lowerLimit': '33.0', 'upperLimit': '47.8'}, {'value': '37.0', 'groupId': 'OG001', 'lowerLimit': '30.0', 'upperLimit': '44.5'}]}]}, {'title': 'Week 32', 'categories': [{'measurements': [{'value': '44.1', 'groupId': 'OG000', 'lowerLimit': '36.7', 'upperLimit': '51.7'}, {'value': '30.4', 'groupId': 'OG001', 'lowerLimit': '23.8', 'upperLimit': '37.6'}]}]}, {'title': 'Week 36', 'categories': [{'measurements': [{'value': '45.3', 'groupId': 'OG000', 'lowerLimit': '37.8', 'upperLimit': '52.8'}, {'value': '32.6', 'groupId': 'OG001', 'lowerLimit': '25.8', 'upperLimit': '39.9'}]}]}, {'title': 'Week 40', 'categories': [{'measurements': [{'value': '44.7', 'groupId': 'OG000', 'lowerLimit': '37.3', 'upperLimit': '52.3'}, {'value': '31.5', 'groupId': 'OG001', 'lowerLimit': '24.8', 'upperLimit': '38.8'}]}]}, {'title': 'Week 44', 'categories': [{'measurements': [{'value': '50.3', 'groupId': 'OG000', 'lowerLimit': '42.7', 'upperLimit': '57.8'}, {'value': '35.4', 'groupId': 'OG001', 'lowerLimit': '28.4', 'upperLimit': '42.8'}]}]}, {'title': 'Week 48', 'categories': [{'measurements': [{'value': '41.9', 'groupId': 'OG000', 'lowerLimit': '34.6', 'upperLimit': '49.5'}, {'value': '37.0', 'groupId': 'OG001', 'lowerLimit': '30.0', 'upperLimit': '44.5'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'value': '46.4', 'groupId': 'OG000', 'lowerLimit': '38.9', 'upperLimit': '54.0'}, {'value': '37.6', 'groupId': 'OG001', 'lowerLimit': '30.5', 'upperLimit': '45.1'}]}]}, {'title': 'Week 56', 'categories': [{'measurements': [{'value': '46.4', 'groupId': 'OG000', 'lowerLimit': '38.9', 'upperLimit': '54.0'}, {'value': '35.9', 'groupId': 'OG001', 'lowerLimit': '28.9', 'upperLimit': '43.4'}]}]}, {'title': 'Week 60', 'categories': [{'measurements': [{'value': '46.9', 'groupId': 'OG000', 'lowerLimit': '39.4', 'upperLimit': '54.5'}, {'value': '38.7', 'groupId': 'OG001', 'lowerLimit': '31.5', 'upperLimit': '46.2'}]}]}, {'title': 'Week 64', 'categories': [{'measurements': [{'value': '50.3', 'groupId': 'OG000', 'lowerLimit': '42.7', 'upperLimit': '57.8'}, {'value': '36.5', 'groupId': 'OG001', 'lowerLimit': '29.5', 'upperLimit': '43.9'}]}]}, {'title': 'Week 68', 'categories': [{'measurements': [{'value': '48.6', 'groupId': 'OG000', 'lowerLimit': '41.1', 'upperLimit': '56.2'}, {'value': '35.9', 'groupId': 'OG001', 'lowerLimit': '28.9', 'upperLimit': '43.4'}]}]}, {'title': 'Week 72', 'categories': [{'measurements': [{'value': '48.0', 'groupId': 'OG000', 'lowerLimit': '40.5', 'upperLimit': '55.6'}, {'value': '35.4', 'groupId': 'OG001', 'lowerLimit': '28.4', 'upperLimit': '42.8'}]}]}, {'title': 'Week 76', 'categories': [{'measurements': [{'value': '46.4', 'groupId': 'OG000', 'lowerLimit': '38.9', 'upperLimit': '54.0'}, {'value': '40.9', 'groupId': 'OG001', 'lowerLimit': '33.6', 'upperLimit': '48.4'}]}]}, {'title': 'Week 80', 'categories': [{'measurements': [{'value': '43.6', 'groupId': 'OG000', 'lowerLimit': '36.2', 'upperLimit': '51.2'}, {'value': '37.6', 'groupId': 'OG001', 'lowerLimit': '30.5', 'upperLimit': '45.1'}]}]}, {'title': 'Week 84', 'categories': [{'measurements': [{'value': '46.4', 'groupId': 'OG000', 'lowerLimit': '38.9', 'upperLimit': '54.0'}, {'value': '37.0', 'groupId': 'OG001', 'lowerLimit': '30.0', 'upperLimit': '44.5'}]}]}, {'title': 'Week 88', 'categories': [{'measurements': [{'value': '47.5', 'groupId': 'OG000', 'lowerLimit': '40.0', 'upperLimit': '55.1'}, {'value': '40.9', 'groupId': 'OG001', 'lowerLimit': '33.6', 'upperLimit': '48.4'}]}]}, {'title': 'Week 92', 'categories': [{'measurements': [{'value': '44.7', 'groupId': 'OG000', 'lowerLimit': '37.3', 'upperLimit': '52.3'}, {'value': '40.3', 'groupId': 'OG001', 'lowerLimit': '33.1', 'upperLimit': '47.9'}]}]}, {'title': 'Week 96', 'categories': [{'measurements': [{'value': '46.9', 'groupId': 'OG000', 'lowerLimit': '39.4', 'upperLimit': '54.5'}, {'value': '38.1', 'groupId': 'OG001', 'lowerLimit': '31.0', 'upperLimit': '45.6'}]}]}, {'title': 'Week 100', 'categories': [{'measurements': [{'value': '49.7', 'groupId': 'OG000', 'lowerLimit': '42.2', 'upperLimit': '57.3'}, {'value': '37.6', 'groupId': 'OG001', 'lowerLimit': '30.5', 'upperLimit': '45.1'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '9.6', 'ciLowerLimit': '-0.4', 'ciUpperLimit': '20.2', 'groupDescription': 'Gain of \\>= 15 letters in BCVA at Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '13.6', 'ciLowerLimit': '3.3', 'ciUpperLimit': '23.5', 'groupDescription': 'Gain of \\>= 15 letters in BCVA at Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Lost >= 5 ETDRS Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Each Post-baseline Visit for the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '3.4', 'groupId': 'OG000', 'lowerLimit': '1.2', 'upperLimit': '7.2'}, {'value': '4.4', 'groupId': 'OG001', 'lowerLimit': '1.9', 'upperLimit': '8.5'}]}]}, {'title': 'Week 6', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '3.3', 'groupId': 'OG001', 'lowerLimit': '1.2', 'upperLimit': '7.1'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '1.1', 'groupId': 'OG000', 'lowerLimit': '0.1', 'upperLimit': '4.0'}, {'value': '2.8', 'groupId': 'OG001', 'lowerLimit': '0.9', 'upperLimit': '6.3'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '1.1', 'groupId': 'OG000', 'lowerLimit': '0.1', 'upperLimit': '4.0'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '0.6', 'groupId': 'OG000', 'lowerLimit': '0.0', 'upperLimit': '3.1'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 18', 'categories': [{'measurements': [{'value': '1.1', 'groupId': 'OG000', 'lowerLimit': '0.1', 'upperLimit': '4.0'}, {'value': '1.1', 'groupId': 'OG001', 'lowerLimit': '0.1', 'upperLimit': '3.9'}]}]}, {'title': 'Week 20', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '2.8', 'groupId': 'OG001', 'lowerLimit': '0.9', 'upperLimit': '6.3'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '3.3', 'groupId': 'OG001', 'lowerLimit': '1.2', 'upperLimit': '7.1'}]}]}, {'title': 'Week 28', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 32', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 36', 'categories': [{'measurements': [{'value': '4.5', 'groupId': 'OG000', 'lowerLimit': '1.9', 'upperLimit': '8.6'}, {'value': '1.1', 'groupId': 'OG001', 'lowerLimit': '0.1', 'upperLimit': '3.9'}]}]}, {'title': 'Week 40', 'categories': [{'measurements': [{'value': '3.9', 'groupId': 'OG000', 'lowerLimit': '1.6', 'upperLimit': '7.9'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 44', 'categories': [{'measurements': [{'value': '2.8', 'groupId': 'OG000', 'lowerLimit': '0.9', 'upperLimit': '6.4'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 48', 'categories': [{'measurements': [{'value': '2.8', 'groupId': 'OG000', 'lowerLimit': '0.9', 'upperLimit': '6.4'}, {'value': '2.8', 'groupId': 'OG001', 'lowerLimit': '0.9', 'upperLimit': '6.3'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'value': '3.4', 'groupId': 'OG000', 'lowerLimit': '1.2', 'upperLimit': '7.2'}, {'value': '3.3', 'groupId': 'OG001', 'lowerLimit': '1.2', 'upperLimit': '7.1'}]}]}, {'title': 'Week 56', 'categories': [{'measurements': [{'value': '5.0', 'groupId': 'OG000', 'lowerLimit': '2.3', 'upperLimit': '9.3'}, {'value': '3.3', 'groupId': 'OG001', 'lowerLimit': '1.2', 'upperLimit': '7.1'}]}]}, {'title': 'Week 60', 'categories': [{'measurements': [{'value': '3.9', 'groupId': 'OG000', 'lowerLimit': '1.6', 'upperLimit': '7.9'}, {'value': '4.4', 'groupId': 'OG001', 'lowerLimit': '1.9', 'upperLimit': '8.5'}]}]}, {'title': 'Week 64', 'categories': [{'measurements': [{'value': '2.8', 'groupId': 'OG000', 'lowerLimit': '0.9', 'upperLimit': '6.4'}, {'value': '3.3', 'groupId': 'OG001', 'lowerLimit': '1.2', 'upperLimit': '7.1'}]}]}, {'title': 'Week 68', 'categories': [{'measurements': [{'value': '3.9', 'groupId': 'OG000', 'lowerLimit': '1.6', 'upperLimit': '7.9'}, {'value': '2.8', 'groupId': 'OG001', 'lowerLimit': '0.9', 'upperLimit': '6.3'}]}]}, {'title': 'Week 72', 'categories': [{'measurements': [{'value': '4.5', 'groupId': 'OG000', 'lowerLimit': '1.9', 'upperLimit': '8.6'}, {'value': '5.0', 'groupId': 'OG001', 'lowerLimit': '2.3', 'upperLimit': '9.2'}]}]}, {'title': 'Week 76', 'categories': [{'measurements': [{'value': '3.4', 'groupId': 'OG000', 'lowerLimit': '1.2', 'upperLimit': '7.2'}, {'value': '4.4', 'groupId': 'OG001', 'lowerLimit': '1.9', 'upperLimit': '8.5'}]}]}, {'title': 'Week 80', 'categories': [{'measurements': [{'value': '2.8', 'groupId': 'OG000', 'lowerLimit': '0.9', 'upperLimit': '6.4'}, {'value': '6.1', 'groupId': 'OG001', 'lowerLimit': '3.1', 'upperLimit': '10.6'}]}]}, {'title': 'Week 84', 'categories': [{'measurements': [{'value': '3.4', 'groupId': 'OG000', 'lowerLimit': '1.2', 'upperLimit': '7.2'}, {'value': '7.7', 'groupId': 'OG001', 'lowerLimit': '4.3', 'upperLimit': '12.6'}]}]}, {'title': 'Week 88', 'categories': [{'measurements': [{'value': '3.9', 'groupId': 'OG000', 'lowerLimit': '1.6', 'upperLimit': '7.9'}, {'value': '7.2', 'groupId': 'OG001', 'lowerLimit': '3.9', 'upperLimit': '12.0'}]}]}, {'title': 'Week 92', 'categories': [{'measurements': [{'value': '3.4', 'groupId': 'OG000', 'lowerLimit': '1.2', 'upperLimit': '7.2'}, {'value': '6.6', 'groupId': 'OG001', 'lowerLimit': '3.5', 'upperLimit': '11.3'}]}]}, {'title': 'Week 96', 'categories': [{'measurements': [{'value': '3.9', 'groupId': 'OG000', 'lowerLimit': '1.6', 'upperLimit': '7.9'}, {'value': '7.2', 'groupId': 'OG001', 'lowerLimit': '3.9', 'upperLimit': '12.0'}]}]}, {'title': 'Week 100', 'categories': [{'measurements': [{'value': '2.8', 'groupId': 'OG000', 'lowerLimit': '0.9', 'upperLimit': '6.4'}, {'value': '8.3', 'groupId': 'OG001', 'lowerLimit': '4.7', 'upperLimit': '13.3'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.4', 'ciLowerLimit': '-4.2', 'ciUpperLimit': '2.9', 'groupDescription': 'Loss of \\>= 5 letters in BCVA at Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-6.0', 'ciLowerLimit': '-10.8', 'ciUpperLimit': '-1.7', 'groupDescription': 'Loss of \\>= 5 letters in BCVA at Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Lost >= 10 ETDRS Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Each Post-baseline Visit for the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '1.1', 'groupId': 'OG001', 'lowerLimit': '0.1', 'upperLimit': '3.9'}]}]}, {'title': 'Week 6', 'categories': [{'measurements': [{'value': '1.1', 'groupId': 'OG000', 'lowerLimit': '0.1', 'upperLimit': '4.0'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '1.1', 'groupId': 'OG000', 'lowerLimit': '0.1', 'upperLimit': '4.0'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '0.6', 'groupId': 'OG000', 'lowerLimit': '0.0', 'upperLimit': '3.1'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 18', 'categories': [{'measurements': [{'value': '1.1', 'groupId': 'OG000', 'lowerLimit': '0.1', 'upperLimit': '4.0'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 20', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '1.1', 'groupId': 'OG001', 'lowerLimit': '0.1', 'upperLimit': '3.9'}]}]}, {'title': 'Week 28', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 32', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 36', 'categories': [{'measurements': [{'value': '3.4', 'groupId': 'OG000', 'lowerLimit': '1.2', 'upperLimit': '7.2'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 40', 'categories': [{'measurements': [{'value': '2.8', 'groupId': 'OG000', 'lowerLimit': '0.9', 'upperLimit': '6.4'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 44', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 48', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 56', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '1.1', 'groupId': 'OG001', 'lowerLimit': '0.1', 'upperLimit': '3.9'}]}]}, {'title': 'Week 60', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '1.7', 'groupId': 'OG001', 'lowerLimit': '0.3', 'upperLimit': '4.8'}]}]}, {'title': 'Week 64', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 68', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 72', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '1.7', 'groupId': 'OG001', 'lowerLimit': '0.3', 'upperLimit': '4.8'}]}]}, {'title': 'Week 76', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 80', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '1.7', 'groupId': 'OG001', 'lowerLimit': '0.3', 'upperLimit': '4.8'}]}]}, {'title': 'Week 84', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '4.4', 'groupId': 'OG001', 'lowerLimit': '1.9', 'upperLimit': '8.5'}]}]}, {'title': 'Week 88', 'categories': [{'measurements': [{'value': '2.8', 'groupId': 'OG000', 'lowerLimit': '0.9', 'upperLimit': '6.4'}, {'value': '3.9', 'groupId': 'OG001', 'lowerLimit': '1.6', 'upperLimit': '7.8'}]}]}, {'title': 'Week 92', 'categories': [{'measurements': [{'value': '2.8', 'groupId': 'OG000', 'lowerLimit': '0.9', 'upperLimit': '6.3'}, {'value': '2.8', 'groupId': 'OG001', 'lowerLimit': '0.9', 'upperLimit': '6.3'}]}]}, {'title': 'Week 96', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '3.9', 'groupId': 'OG001', 'lowerLimit': '1.6', 'upperLimit': '7.8'}]}]}, {'title': 'Week 100', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '6.1', 'groupId': 'OG001', 'lowerLimit': '3.1', 'upperLimit': '10.6'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.2', 'ciLowerLimit': '-3.2', 'ciUpperLimit': '2.4', 'groupDescription': 'Loss of \\>= 10 letters in BCVA at Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-4.1', 'ciLowerLimit': '-8.4', 'ciUpperLimit': '-0.1', 'groupDescription': 'Loss of \\>= 10 letters in BCVA at Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Lost >= 15 ETDRS Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Each Post-baseline Visit for the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 6', 'categories': [{'measurements': [{'value': '1.1', 'groupId': 'OG000', 'lowerLimit': '0.1', 'upperLimit': '4.0'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '0.6', 'groupId': 'OG000', 'lowerLimit': '0.0', 'upperLimit': '3.1'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '0.6', 'groupId': 'OG000', 'lowerLimit': '0.0', 'upperLimit': '3.1'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 18', 'categories': [{'measurements': [{'value': '1.1', 'groupId': 'OG000', 'lowerLimit': '0.1', 'upperLimit': '4.0'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 20', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'value': '1.1', 'groupId': 'OG000', 'lowerLimit': '0.1', 'upperLimit': '4.0'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 28', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 32', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 36', 'categories': [{'measurements': [{'value': '2.8', 'groupId': 'OG000', 'lowerLimit': '0.9', 'upperLimit': '6.4'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 40', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 44', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 48', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'value': '1.1', 'groupId': 'OG000', 'lowerLimit': '0.1', 'upperLimit': '4.0'}, {'value': '1.7', 'groupId': 'OG001', 'lowerLimit': '0.3', 'upperLimit': '4.8'}]}]}, {'title': 'Week 56', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '1.1', 'groupId': 'OG001', 'lowerLimit': '0.1', 'upperLimit': '3.9'}]}]}, {'title': 'Week 60', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '1.7', 'groupId': 'OG001', 'lowerLimit': '0.3', 'upperLimit': '4.8'}]}]}, {'title': 'Week 64', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 68', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 72', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '1.1', 'groupId': 'OG001', 'lowerLimit': '0.1', 'upperLimit': '3.9'}]}]}, {'title': 'Week 76', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 80', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 84', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 88', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 92', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 96', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 100', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '3.3', 'groupId': 'OG001', 'lowerLimit': '1.2', 'upperLimit': '7.1'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.7', 'ciLowerLimit': '-3.2', 'ciUpperLimit': '1.6', 'groupDescription': 'Loss of \\>= 15 letters in BCVA at Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.3', 'ciLowerLimit': '-4.8', 'ciUpperLimit': '2.0', 'groupDescription': 'Loss of \\>= 15 letters in BCVA at Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With an Absolute Best Corrected Visual Acuity (BCVA) >= 73 ETDRS Letters at Each Post-baseline Visit for the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '55.3', 'groupId': 'OG000', 'lowerLimit': '47.7', 'upperLimit': '62.7'}, {'value': '42.5', 'groupId': 'OG001', 'lowerLimit': '35.2', 'upperLimit': '50.1'}]}]}, {'title': 'Week 6', 'categories': [{'measurements': [{'value': '64.8', 'groupId': 'OG000', 'lowerLimit': '57.3', 'upperLimit': '71.8'}, {'value': '49.7', 'groupId': 'OG001', 'lowerLimit': '42.2', 'upperLimit': '57.2'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '66.5', 'groupId': 'OG000', 'lowerLimit': '59.1', 'upperLimit': '73.3'}, {'value': '50.8', 'groupId': 'OG001', 'lowerLimit': '43.3', 'upperLimit': '58.3'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '66.5', 'groupId': 'OG000', 'lowerLimit': '59.1', 'upperLimit': '73.3'}, {'value': '59.7', 'groupId': 'OG001', 'lowerLimit': '52.1', 'upperLimit': '66.9'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '69.8', 'groupId': 'OG000', 'lowerLimit': '62.5', 'upperLimit': '76.5'}, {'value': '60.8', 'groupId': 'OG001', 'lowerLimit': '53.3', 'upperLimit': '67.9'}]}]}, {'title': 'Week 18', 'categories': [{'measurements': [{'value': '71.5', 'groupId': 'OG000', 'lowerLimit': '64.3', 'upperLimit': '78.0'}, {'value': '64.6', 'groupId': 'OG001', 'lowerLimit': '57.2', 'upperLimit': '71.6'}]}]}, {'title': 'Week 20', 'categories': [{'measurements': [{'value': '71.5', 'groupId': 'OG000', 'lowerLimit': '64.3', 'upperLimit': '78.0'}, {'value': '61.3', 'groupId': 'OG001', 'lowerLimit': '53.8', 'upperLimit': '68.5'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'value': '73.2', 'groupId': 'OG000', 'lowerLimit': '66.1', 'upperLimit': '79.5'}, {'value': '60.2', 'groupId': 'OG001', 'lowerLimit': '52.7', 'upperLimit': '67.4'}]}]}, {'title': 'Week 28', 'categories': [{'measurements': [{'value': '72.6', 'groupId': 'OG000', 'lowerLimit': '65.5', 'upperLimit': '79.0'}, {'value': '61.9', 'groupId': 'OG001', 'lowerLimit': '54.4', 'upperLimit': '69.0'}]}]}, {'title': 'Week 32', 'categories': [{'measurements': [{'value': '73.7', 'groupId': 'OG000', 'lowerLimit': '66.7', 'upperLimit': '80.0'}, {'value': '59.1', 'groupId': 'OG001', 'lowerLimit': '51.6', 'upperLimit': '66.4'}]}]}, {'title': 'Week 36', 'categories': [{'measurements': [{'value': '70.4', 'groupId': 'OG000', 'lowerLimit': '63.1', 'upperLimit': '77.0'}, {'value': '65.2', 'groupId': 'OG001', 'lowerLimit': '57.8', 'upperLimit': '72.1'}]}]}, {'title': 'Week 40', 'categories': [{'measurements': [{'value': '69.8', 'groupId': 'OG000', 'lowerLimit': '62.5', 'upperLimit': '76.5'}, {'value': '60.2', 'groupId': 'OG001', 'lowerLimit': '52.7', 'upperLimit': '67.4'}]}]}, {'title': 'Week 44', 'categories': [{'measurements': [{'value': '73.7', 'groupId': 'OG000', 'lowerLimit': '66.7', 'upperLimit': '80.0'}, {'value': '63.5', 'groupId': 'OG001', 'lowerLimit': '56.1', 'upperLimit': '70.5'}]}]}, {'title': 'Week 48', 'categories': [{'measurements': [{'value': '70.9', 'groupId': 'OG000', 'lowerLimit': '63.7', 'upperLimit': '77.5'}, {'value': '61.3', 'groupId': 'OG001', 'lowerLimit': '53.8', 'upperLimit': '68.5'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'value': '73.7', 'groupId': 'OG000', 'lowerLimit': '66.7', 'upperLimit': '80.0'}, {'value': '64.6', 'groupId': 'OG001', 'lowerLimit': '57.2', 'upperLimit': '71.6'}]}]}, {'title': 'Week 56', 'categories': [{'measurements': [{'value': '72.6', 'groupId': 'OG000', 'lowerLimit': '65.5', 'upperLimit': '79.0'}, {'value': '66.9', 'groupId': 'OG001', 'lowerLimit': '59.5', 'upperLimit': '73.7'}]}]}, {'title': 'Week 60', 'categories': [{'measurements': [{'value': '70.9', 'groupId': 'OG000', 'lowerLimit': '63.7', 'upperLimit': '77.5'}, {'value': '66.9', 'groupId': 'OG001', 'lowerLimit': '59.5', 'upperLimit': '73.7'}]}]}, {'title': 'Week 64', 'categories': [{'measurements': [{'value': '74.3', 'groupId': 'OG000', 'lowerLimit': '67.2', 'upperLimit': '80.5'}, {'value': '68.5', 'groupId': 'OG001', 'lowerLimit': '61.2', 'upperLimit': '75.2'}]}]}, {'title': 'Week 68', 'categories': [{'measurements': [{'value': '71.5', 'groupId': 'OG000', 'lowerLimit': '64.3', 'upperLimit': '78.0'}, {'value': '66.3', 'groupId': 'OG001', 'lowerLimit': '58.9', 'upperLimit': '73.1'}]}]}, {'title': 'Week 72', 'categories': [{'measurements': [{'value': '73.7', 'groupId': 'OG000', 'lowerLimit': '66.7', 'upperLimit': '80.0'}, {'value': '65.2', 'groupId': 'OG001', 'lowerLimit': '57.8', 'upperLimit': '72.1'}]}]}, {'title': 'Week 76', 'categories': [{'measurements': [{'value': '72.6', 'groupId': 'OG000', 'lowerLimit': '65.5', 'upperLimit': '79.0'}, {'value': '66.9', 'groupId': 'OG001', 'lowerLimit': '59.5', 'upperLimit': '73.7'}]}]}, {'title': 'Week 80', 'categories': [{'measurements': [{'value': '70.9', 'groupId': 'OG000', 'lowerLimit': '63.7', 'upperLimit': '77.5'}, {'value': '64.1', 'groupId': 'OG001', 'lowerLimit': '56.6', 'upperLimit': '71.1'}]}]}, {'title': 'Week 84', 'categories': [{'measurements': [{'value': '70.9', 'groupId': 'OG000', 'lowerLimit': '63.7', 'upperLimit': '77.5'}, {'value': '65.2', 'groupId': 'OG001', 'lowerLimit': '57.8', 'upperLimit': '72.1'}]}]}, {'title': 'Week 88', 'categories': [{'measurements': [{'value': '72.6', 'groupId': 'OG000', 'lowerLimit': '65.5', 'upperLimit': '79.0'}, {'value': '63.5', 'groupId': 'OG001', 'lowerLimit': '56.1', 'upperLimit': '70.5'}]}]}, {'title': 'Week 92', 'categories': [{'measurements': [{'value': '71.5', 'groupId': 'OG000', 'lowerLimit': '64.3', 'upperLimit': '78.0'}, {'value': '63.5', 'groupId': 'OG001', 'lowerLimit': '56.1', 'upperLimit': '70.5'}]}]}, {'title': 'Week 96', 'categories': [{'measurements': [{'value': '70.4', 'groupId': 'OG000', 'lowerLimit': '63.1', 'upperLimit': '77.0'}, {'value': '62.4', 'groupId': 'OG001', 'lowerLimit': '54.9', 'upperLimit': '69.5'}]}]}, {'title': 'Week 100', 'categories': [{'measurements': [{'value': '70.9', 'groupId': 'OG000', 'lowerLimit': '63.7', 'upperLimit': '77.5'}, {'value': '62.4', 'groupId': 'OG001', 'lowerLimit': '54.9', 'upperLimit': '69.5'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.5', 'ciLowerLimit': '-4.9', 'ciUpperLimit': '12.0', 'groupDescription': 'Absolute BCVA \\>= 73 letters at Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.6', 'ciLowerLimit': '-5.4', 'ciUpperLimit': '12.6', 'groupDescription': 'Absolute BCVA \\>= 73 letters at Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Mean Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit for the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-128.2', 'spread': '131.47', 'groupId': 'OG000'}, {'value': '-113.9', 'spread': '123.20', 'groupId': 'OG001'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-136.9', 'spread': '135.57', 'groupId': 'OG000'}, {'value': '-126.0', 'spread': '124.82', 'groupId': 'OG001'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-155.4', 'spread': '139.09', 'groupId': 'OG000'}, {'value': '-130.8', 'spread': '124.71', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-160.8', 'spread': '137.23', 'groupId': 'OG000'}, {'value': '-137.9', 'spread': '132.30', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-179.1', 'spread': '137.26', 'groupId': 'OG000'}, {'value': '-145.3', 'spread': '132.63', 'groupId': 'OG001'}]}]}, {'title': 'Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-175.8', 'spread': '139.10', 'groupId': 'OG000'}, {'value': '-149.0', 'spread': '132.28', 'groupId': 'OG001'}]}]}, {'title': 'Week 20', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-183.7', 'spread': '139.76', 'groupId': 'OG000'}, {'value': '-151.0', 'spread': '130.98', 'groupId': 'OG001'}]}]}, {'title': 'Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-183.3', 'spread': '143.14', 'groupId': 'OG000'}, {'value': '-134.0', 'spread': '136.67', 'groupId': 'OG001'}]}]}, {'title': 'Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-192.0', 'spread': '145.85', 'groupId': 'OG000'}, {'value': '-161.4', 'spread': '131.27', 'groupId': 'OG001'}]}]}, {'title': 'Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-178.6', 'spread': '138.5', 'groupId': 'OG000'}, {'value': '-144.9', 'spread': '135.93', 'groupId': 'OG001'}]}]}, {'title': 'Week 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-163.5', 'spread': '144.34', 'groupId': 'OG000'}, {'value': '-162.9', 'spread': '135.19', 'groupId': 'OG001'}]}]}, {'title': 'Week 40', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-183.3', 'spread': '139.84', 'groupId': 'OG000'}, {'value': '-149.9', 'spread': '132.66', 'groupId': 'OG001'}]}]}, {'title': 'Week 44', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-193.3', 'spread': '144.12', 'groupId': 'OG000'}, {'value': '-163.5', 'spread': '133.01', 'groupId': 'OG001'}]}]}, {'title': 'Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-172.8', 'spread': '141.83', 'groupId': 'OG000'}, {'value': '-154.6', 'spread': '130.54', 'groupId': 'OG001'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-196.5', 'spread': '144.44', 'groupId': 'OG000'}, {'value': '-165.0', 'spread': '134.77', 'groupId': 'OG001'}]}]}, {'title': 'Week 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-191.08', 'spread': '148.02', 'groupId': 'OG000'}, {'value': '-162.4', 'spread': '132.53', 'groupId': 'OG001'}]}]}, {'title': 'Week 60', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-189.8', 'spread': '147.93', 'groupId': 'OG000'}, {'value': '-166.2', 'spread': '132.61', 'groupId': 'OG001'}]}]}, {'title': 'Week 64', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-193.2', 'spread': '143.36', 'groupId': 'OG000'}, {'value': '-160.2', 'spread': '137.83', 'groupId': 'OG001'}]}]}, {'title': 'Week 68', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-194.5', 'spread': '141.47', 'groupId': 'OG000'}, {'value': '-169.8', 'spread': '143.97', 'groupId': 'OG001'}]}]}, {'title': 'Week 72', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-190.4', 'spread': '142.25', 'groupId': 'OG000'}, {'value': '-165.1', 'spread': '141.38', 'groupId': 'OG001'}]}]}, {'title': 'Week 76', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-185.6', 'spread': '143.68', 'groupId': 'OG000'}, {'value': '-174.7', 'spread': '138.70', 'groupId': 'OG001'}]}]}, {'title': 'Week 80', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-185.7', 'spread': '145.52', 'groupId': 'OG000'}, {'value': '-171.1', 'spread': '138.53', 'groupId': 'OG001'}]}]}, {'title': 'Week 84', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-193.5', 'spread': '142.53', 'groupId': 'OG000'}, {'value': '-175.1', 'spread': '139.76', 'groupId': 'OG001'}]}]}, {'title': 'Week 88', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-191.0', 'spread': '141.29', 'groupId': 'OG000'}, {'value': '-172.2', 'spread': '138.08', 'groupId': 'OG001'}]}]}, {'title': 'Week 92', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-193.8', 'spread': '142.07', 'groupId': 'OG000'}, {'value': '-180.1', 'spread': '138.88', 'groupId': 'OG001'}]}]}, {'title': 'Week 96', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-197.2', 'spread': '144.29', 'groupId': 'OG000'}, {'value': '-170.2', 'spread': '154.37', 'groupId': 'OG001'}]}]}, {'title': 'Week 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-201.4', 'spread': '142.90', 'groupId': 'OG000'}, {'value': '-173.9', 'spread': '152.03', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'The thickness of the retina was measured using Spectral Domain (SD) optical coherence tomography (OCT) equipment (SD-OCT) and reported as a difference, in micrometers. a negative change from baseline indicates a reduction in thickness, whereas a positive change from baseline indicates an increase. An increase in thickness may indicate a progression of the underlying disease. CSFT assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Micrometers', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Average Mean Change From Baseline in Central Subfield Thickness (CSFT) Over the Period Week 40 Through Week 52 / Week 88 Through Week 100 for the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'period Week 40 through Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-187.1', 'groupId': 'OG000', 'lowerLimit': '-200.7', 'upperLimit': '-173.5'}, {'value': '-157.7', 'groupId': 'OG001', 'lowerLimit': '-171.2', 'upperLimit': '-144.1'}]}]}, {'title': 'period Week 88 through Week 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-196.6', 'groupId': 'OG000', 'lowerLimit': '-210.9', 'upperLimit': '-182.3'}, {'value': '-173.4', 'groupId': 'OG001', 'lowerLimit': '-187.6', 'upperLimit': '-159.1'}]}]}], 'analyses': [{'pValue': '<0.003', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-29.4', 'ciLowerLimit': '-48.6', 'ciUpperLimit': '-10.2', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '9.76', 'groupDescription': 'CSFT over period Week 40 through Week 52', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'pValue': '0.001', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'CSFT over period Week 40 through Week 52', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'LS mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-23.2', 'ciLowerLimit': '-43.5', 'ciUpperLimit': '-3.0', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.28', 'groupDescription': 'CSFT over period Week 88 through Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, period Week 40 through Week 52, period Week 88 through Week 100', 'description': 'The thickness of the retina was measured using Spectral Domain (SD) optical coherence tomography (OCT) equipment (SD-OCT) and reported as a difference, in micrometers. a negative change from baseline indicates a reduction in thickness, whereas a positive change from baseline indicates an increase. An increase in thickness may indicate a progression of the underlying disease. CSFT assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment. For each participants, this endpoint was derived as the average of the changes from Baseline to Weeks 40, 44, 48, 52. Then the same was derived over the period Week 88 through Week 100, considering the average of the changes from Baseline to Weeks 88, 92, 96, 100. This endpoint was only assessed in the year-2 analysis (Week 100).', 'unitOfMeasure': 'Micrometers', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Average Mean Change From Baseline in CSFT Over the Period Week 4 to Week 52 / 100 for the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'period Week 4 through Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-172.8', 'groupId': 'OG000', 'lowerLimit': '-185.8', 'upperLimit': '-159.8'}, {'value': '-145.4', 'groupId': 'OG001', 'lowerLimit': '-158.4', 'upperLimit': '-132.4'}]}]}, {'title': 'period Week 4 through Week 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-181.8', 'groupId': 'OG000', 'lowerLimit': '-194.7', 'upperLimit': '-168.9'}, {'value': '-156.1', 'groupId': 'OG001', 'lowerLimit': '-169.0', 'upperLimit': '-143.2'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'LS mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-27.4', 'ciLowerLimit': '-45.8', 'ciUpperLimit': '-9.0', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '9.35', 'groupDescription': 'CSFT over period Week 4 through Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'LS mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-25.8', 'ciLowerLimit': '-44.0', 'ciUpperLimit': '-7.5', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '9.29', 'groupDescription': 'CSFT over period Week 4 through Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, period Week 4 through Week 52, period Week 4 through Week 100', 'description': 'The thickness of the retina was measured using Spectral Domain (SD) optical coherence tomography (OCT) equipment (SD-OCT) and reported as a difference, in micrometers. a negative change from baseline indicates a reduction in thickness, whereas a positive change from baseline indicates an increase. An increase in thickness may indicate a progression of the underlying disease. CSFT assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Micrometers', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Normal CSFT Thickness (<280 Micrometers) at Each Post-baseline Visit for the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '12.8', 'groupId': 'OG000', 'lowerLimit': '8.3', 'upperLimit': '18.7'}, {'value': '13.3', 'groupId': 'OG001', 'lowerLimit': '8.7', 'upperLimit': '19.2'}]}]}, {'title': 'Week 6', 'categories': [{'measurements': [{'value': '16.8', 'groupId': 'OG000', 'lowerLimit': '11.6', 'upperLimit': '23.1'}, {'value': '14.4', 'groupId': 'OG001', 'lowerLimit': '9.7', 'upperLimit': '20.4'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '22.9', 'groupId': 'OG000', 'lowerLimit': '17.0', 'upperLimit': '29.8'}, {'value': '16.7', 'groupId': 'OG001', 'lowerLimit': '11.5', 'upperLimit': '22.9'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '30.2', 'groupId': 'OG000', 'lowerLimit': '23.5', 'upperLimit': '37.5'}, {'value': '24.4', 'groupId': 'OG001', 'lowerLimit': '18.4', 'upperLimit': '31.4'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '36.9', 'groupId': 'OG000', 'lowerLimit': '29.8', 'upperLimit': '44.4'}, {'value': '29.4', 'groupId': 'OG001', 'lowerLimit': '22.9', 'upperLimit': '36.7'}]}]}, {'title': 'Week 18', 'categories': [{'measurements': [{'value': '39.1', 'groupId': 'OG000', 'lowerLimit': '31.9', 'upperLimit': '46.7'}, {'value': '30.0', 'groupId': 'OG001', 'lowerLimit': '23.4', 'upperLimit': '37.3'}]}]}, {'title': 'Week 20', 'categories': [{'measurements': [{'value': '42.5', 'groupId': 'OG000', 'lowerLimit': '35.1', 'upperLimit': '50.1'}, {'value': '31.1', 'groupId': 'OG001', 'lowerLimit': '24.4', 'upperLimit': '38.4'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'value': '48.6', 'groupId': 'OG000', 'lowerLimit': '41.1', 'upperLimit': '56.2'}, {'value': '29.4', 'groupId': 'OG001', 'lowerLimit': '22.9', 'upperLimit': '36.7'}]}]}, {'title': 'Week 28', 'categories': [{'measurements': [{'value': '50.3', 'groupId': 'OG000', 'lowerLimit': '42.7', 'upperLimit': '57.8'}, {'value': '33.9', 'groupId': 'OG001', 'lowerLimit': '27.0', 'upperLimit': '41.3'}]}]}, {'title': 'Week 32', 'categories': [{'measurements': [{'value': '48.0', 'groupId': 'OG000', 'lowerLimit': '40.5', 'upperLimit': '55.6'}, {'value': '30.6', 'groupId': 'OG001', 'lowerLimit': '23.9', 'upperLimit': '37.8'}]}]}, {'title': 'Week 36', 'categories': [{'measurements': [{'value': '38.5', 'groupId': 'OG000', 'lowerLimit': '31.4', 'upperLimit': '46.1'}, {'value': '38.9', 'groupId': 'OG001', 'lowerLimit': '31.7', 'upperLimit': '46.4'}]}]}, {'title': 'Week 40', 'categories': [{'measurements': [{'value': '51.4', 'groupId': 'OG000', 'lowerLimit': '43.8', 'upperLimit': '58.9'}, {'value': '37.2', 'groupId': 'OG001', 'lowerLimit': '30.1', 'upperLimit': '44.7'}]}]}, {'title': 'Week 44', 'categories': [{'measurements': [{'value': '51.4', 'groupId': 'OG000', 'lowerLimit': '43.8', 'upperLimit': '58.9'}, {'value': '38.9', 'groupId': 'OG001', 'lowerLimit': '31.7', 'upperLimit': '46.4'}]}]}, {'title': 'Week 48', 'categories': [{'measurements': [{'value': '49.7', 'groupId': 'OG000', 'lowerLimit': '42.2', 'upperLimit': '57.3'}, {'value': '37.2', 'groupId': 'OG001', 'lowerLimit': '30.1', 'upperLimit': '44.7'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'value': '57.5', 'groupId': 'OG000', 'lowerLimit': '49.9', 'upperLimit': '64.9'}, {'value': '41.4', 'groupId': 'OG001', 'lowerLimit': '34.2', 'upperLimit': '49.0'}]}]}, {'title': 'Week 56', 'categories': [{'measurements': [{'value': '57.5', 'groupId': 'OG000', 'lowerLimit': '49.9', 'upperLimit': '64.9'}, {'value': '40.3', 'groupId': 'OG001', 'lowerLimit': '33.1', 'upperLimit': '47.9'}]}]}, {'title': 'Week 60', 'categories': [{'measurements': [{'value': '53.1', 'groupId': 'OG000', 'lowerLimit': '45.5', 'upperLimit': '60.6'}, {'value': '40.3', 'groupId': 'OG001', 'lowerLimit': '33.1', 'upperLimit': '47.9'}]}]}, {'title': 'Week 64', 'categories': [{'measurements': [{'value': '54.2', 'groupId': 'OG000', 'lowerLimit': '46.6', 'upperLimit': '61.6'}, {'value': '38.1', 'groupId': 'OG001', 'lowerLimit': '31.0', 'upperLimit': '45.6'}]}]}, {'title': 'Week 68', 'categories': [{'measurements': [{'value': '53.6', 'groupId': 'OG000', 'lowerLimit': '46.0', 'upperLimit': '61.1'}, {'value': '41.4', 'groupId': 'OG001', 'lowerLimit': '34.2', 'upperLimit': '49.0'}]}]}, {'title': 'Week 72', 'categories': [{'measurements': [{'value': '56.4', 'groupId': 'OG000', 'lowerLimit': '48.8', 'upperLimit': '63.8'}, {'value': '38.7', 'groupId': 'OG001', 'lowerLimit': '31.5', 'upperLimit': '46.2'}]}]}, {'title': 'Week 76', 'categories': [{'measurements': [{'value': '55.3', 'groupId': 'OG000', 'lowerLimit': '47.7', 'upperLimit': '62.7'}, {'value': '42.5', 'groupId': 'OG001', 'lowerLimit': '35.2', 'upperLimit': '50.1'}]}]}, {'title': 'Week 80', 'categories': [{'measurements': [{'value': '57.0', 'groupId': 'OG000', 'lowerLimit': '49.4', 'upperLimit': '64.3'}, {'value': '39.8', 'groupId': 'OG001', 'lowerLimit': '32.6', 'upperLimit': '47.3'}]}]}, {'title': 'Week 84', 'categories': [{'measurements': [{'value': '57.0', 'groupId': 'OG000', 'lowerLimit': '49.4', 'upperLimit': '64.3'}, {'value': '43.1', 'groupId': 'OG001', 'lowerLimit': '35.8', 'upperLimit': '50.6'}]}]}, {'title': 'Week 88', 'categories': [{'measurements': [{'value': '56.4', 'groupId': 'OG000', 'lowerLimit': '48.8', 'upperLimit': '63.8'}, {'value': '41.4', 'groupId': 'OG001', 'lowerLimit': '34.2', 'upperLimit': '49.0'}]}]}, {'title': 'Week 92', 'categories': [{'measurements': [{'value': '57.0', 'groupId': 'OG000', 'lowerLimit': '49.4', 'upperLimit': '64.3'}, {'value': '45.9', 'groupId': 'OG001', 'lowerLimit': '38.4', 'upperLimit': '53.4'}]}]}, {'title': 'Week 96', 'categories': [{'measurements': [{'value': '59.8', 'groupId': 'OG000', 'lowerLimit': '52.2', 'upperLimit': '67.0'}, {'value': '43.6', 'groupId': 'OG001', 'lowerLimit': '36.3', 'upperLimit': '51.2'}]}]}, {'title': 'Week 100', 'categories': [{'measurements': [{'value': '62.0', 'groupId': 'OG000', 'lowerLimit': '54.5', 'upperLimit': '69.1'}, {'value': '47.0', 'groupId': 'OG001', 'lowerLimit': '39.5', 'upperLimit': '54.5'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '16.3', 'ciLowerLimit': '5.7', 'ciUpperLimit': '25.9', 'groupDescription': 'CSFT thickness (\\<280 micrometers) at Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '14.7', 'ciLowerLimit': '4.2', 'ciUpperLimit': '24.9', 'groupDescription': 'CSFT thickness (\\<280 micrometers) at Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'The thickness of the retina was measured using Spectral Domain (SD) optical coherence tomography (OCT) equipment (SD-OCT) and reported as a difference, in micrometers. CSFT assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Percentage of Patients With Presence of Subretinal Fluid (SRF) in the Study Eye at Each Post-baseline Visit', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '12.3', 'groupId': 'OG000', 'lowerLimit': '7.9', 'upperLimit': '18.0'}, {'value': '19.3', 'groupId': 'OG001', 'lowerLimit': '13.9', 'upperLimit': '25.9'}]}]}, {'title': 'Week 6', 'categories': [{'measurements': [{'value': '10.1', 'groupId': 'OG000', 'lowerLimit': '6.1', 'upperLimit': '15.4'}, {'value': '13.8', 'groupId': 'OG001', 'lowerLimit': '9.1', 'upperLimit': '19.7'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '5.6', 'groupId': 'OG000', 'lowerLimit': '2.7', 'upperLimit': '10.0'}, {'value': '12.2', 'groupId': 'OG001', 'lowerLimit': '7.8', 'upperLimit': '17.8'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '3.9', 'groupId': 'OG000', 'lowerLimit': '1.6', 'upperLimit': '7.9'}, {'value': '7.7', 'groupId': 'OG001', 'lowerLimit': '4.3', 'upperLimit': '12.6'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '3.9', 'groupId': 'OG001', 'lowerLimit': '1.6', 'upperLimit': '7.8'}]}]}, {'title': 'Week 18', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 20', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '3.3', 'groupId': 'OG001', 'lowerLimit': '1.2', 'upperLimit': '7.1'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '6.6', 'groupId': 'OG001', 'lowerLimit': '3.5', 'upperLimit': '11.3'}]}]}, {'title': 'Week 28', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '2.8', 'groupId': 'OG001', 'lowerLimit': '0.9', 'upperLimit': '6.3'}]}]}, {'title': 'Week 32', 'categories': [{'measurements': [{'value': '5.0', 'groupId': 'OG000', 'lowerLimit': '2.3', 'upperLimit': '9.3'}, {'value': '3.9', 'groupId': 'OG001', 'lowerLimit': '1.6', 'upperLimit': '7.8'}]}]}, {'title': 'Week 36', 'categories': [{'measurements': [{'value': '6.7', 'groupId': 'OG000', 'lowerLimit': '3.5', 'upperLimit': '11.4'}, {'value': '1.7', 'groupId': 'OG001', 'lowerLimit': '0.3', 'upperLimit': '4.8'}]}]}, {'title': 'Week 40', 'categories': [{'measurements': [{'value': '4.5', 'groupId': 'OG000', 'lowerLimit': '1.9', 'upperLimit': '8.6'}, {'value': '2.8', 'groupId': 'OG001', 'lowerLimit': '0.9', 'upperLimit': '6.3'}]}]}, {'title': 'Week 44', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '2.8', 'groupId': 'OG001', 'lowerLimit': '0.9', 'upperLimit': '6.3'}]}]}, {'title': 'Week 48', 'categories': [{'measurements': [{'value': '6.1', 'groupId': 'OG000', 'lowerLimit': '3.1', 'upperLimit': '10.7'}, {'value': '5.0', 'groupId': 'OG001', 'lowerLimit': '2.3', 'upperLimit': '9.2'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '3.3', 'groupId': 'OG001', 'lowerLimit': '1.2', 'upperLimit': '7.1'}]}]}, {'title': 'Week 56', 'categories': [{'measurements': [{'value': '2.8', 'groupId': 'OG000', 'lowerLimit': '0.9', 'upperLimit': '6.4'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 60', 'categories': [{'measurements': [{'value': '2.8', 'groupId': 'OG000', 'lowerLimit': '0.9', 'upperLimit': '6.4'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 64', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '3.9', 'groupId': 'OG001', 'lowerLimit': '1.6', 'upperLimit': '7.8'}]}]}, {'title': 'Week 68', 'categories': [{'measurements': [{'value': '3.4', 'groupId': 'OG000', 'lowerLimit': '1.2', 'upperLimit': '7.2'}, {'value': '4.4', 'groupId': 'OG001', 'lowerLimit': '1.9', 'upperLimit': '8.5'}]}]}, {'title': 'Week 72', 'categories': [{'measurements': [{'value': '3.4', 'groupId': 'OG000', 'lowerLimit': '1.2', 'upperLimit': '7.2'}, {'value': '2.8', 'groupId': 'OG001', 'lowerLimit': '0.9', 'upperLimit': '6.3'}]}]}, {'title': 'Week 76', 'categories': [{'measurements': [{'value': '3.9', 'groupId': 'OG000', 'lowerLimit': '1.6', 'upperLimit': '7.9'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 80', 'categories': [{'measurements': [{'value': '4.5', 'groupId': 'OG000', 'lowerLimit': '1.9', 'upperLimit': '8.6'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 84', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 88', 'categories': [{'measurements': [{'value': '3.4', 'groupId': 'OG000', 'lowerLimit': '1.2', 'upperLimit': '7.2'}, {'value': '2.2', 'groupId': 'OG001', 'lowerLimit': '0.6', 'upperLimit': '5.6'}]}]}, {'title': 'Week 92', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.8'}, {'value': '1.1', 'groupId': 'OG001', 'lowerLimit': '0.1', 'upperLimit': '3.9'}]}]}, {'title': 'Week 96', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '2.8', 'groupId': 'OG001', 'lowerLimit': '0.9', 'upperLimit': '6.3'}]}]}, {'title': 'Week 100', 'categories': [{'measurements': [{'value': '2.2', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.6'}, {'value': '2.8', 'groupId': 'OG001', 'lowerLimit': '0.9', 'upperLimit': '6.3'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.2', 'ciLowerLimit': '-4.5', 'ciUpperLimit': '2.1', 'groupDescription': 'Subretinal Fluid (SRF) at Week 52', 'nonInferiorityType': 'OTHER'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.2', 'ciLowerLimit': '-3.4', 'ciUpperLimit': '3.4', 'groupDescription': 'Subretinal Fluid (SRF) at Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment Difference'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Presence of Subretinal Fluid (SRF) in the study eye was assessed by spectral domain optical coherence tomography (SD-OCT), angiography, and/or color fundus photography. Subretinal fluid status assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Percentage of Patients With Presence of Intraretinal Fluid (IRF) in the Study Eye at Each Post-baseline Visit', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '88.3', 'groupId': 'OG000', 'lowerLimit': '82.6', 'upperLimit': '92.6'}, {'value': '89.0', 'groupId': 'OG001', 'lowerLimit': '83.5', 'upperLimit': '93.1'}]}]}, {'title': 'Week 6', 'categories': [{'measurements': [{'value': '85.5', 'groupId': 'OG000', 'lowerLimit': '79.4', 'upperLimit': '90.3'}, {'value': '86.2', 'groupId': 'OG001', 'lowerLimit': '80.3', 'upperLimit': '90.9'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '87.2', 'groupId': 'OG000', 'lowerLimit': '81.3', 'upperLimit': '91.7'}, {'value': '84.5', 'groupId': 'OG001', 'lowerLimit': '78.4', 'upperLimit': '89.5'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '83.8', 'groupId': 'OG000', 'lowerLimit': '77.6', 'upperLimit': '88.9'}, {'value': '85.6', 'groupId': 'OG001', 'lowerLimit': '79.7', 'upperLimit': '90.4'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '76.0', 'groupId': 'OG000', 'lowerLimit': '69.0', 'upperLimit': '82.0'}, {'value': '84.0', 'groupId': 'OG001', 'lowerLimit': '77.8', 'upperLimit': '89.0'}]}]}, {'title': 'Week 18', 'categories': [{'measurements': [{'value': '77.7', 'groupId': 'OG000', 'lowerLimit': '70.8', 'upperLimit': '83.5'}, {'value': '81.2', 'groupId': 'OG001', 'lowerLimit': '74.8', 'upperLimit': '86.6'}]}]}, {'title': 'Week 20', 'categories': [{'measurements': [{'value': '72.6', 'groupId': 'OG000', 'lowerLimit': '65.5', 'upperLimit': '79.0'}, {'value': '79.6', 'groupId': 'OG001', 'lowerLimit': '72.9', 'upperLimit': '85.2'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'value': '69.8', 'groupId': 'OG000', 'lowerLimit': '62.5', 'upperLimit': '76.5'}, {'value': '82.3', 'groupId': 'OG001', 'lowerLimit': '76.0', 'upperLimit': '87.6'}]}]}, {'title': 'Week 28', 'categories': [{'measurements': [{'value': '67.6', 'groupId': 'OG000', 'lowerLimit': '60.2', 'upperLimit': '74.4'}, {'value': '75.1', 'groupId': 'OG001', 'lowerLimit': '68.2', 'upperLimit': '81.3'}]}]}, {'title': 'Week 32', 'categories': [{'measurements': [{'value': '67.6', 'groupId': 'OG000', 'lowerLimit': '60.2', 'upperLimit': '74.4'}, {'value': '76.8', 'groupId': 'OG001', 'lowerLimit': '70.0', 'upperLimit': '82.7'}]}]}, {'title': 'Week 36', 'categories': [{'measurements': [{'value': '73.2', 'groupId': 'OG000', 'lowerLimit': '66.1', 'upperLimit': '79.5'}, {'value': '72.4', 'groupId': 'OG001', 'lowerLimit': '65.3', 'upperLimit': '78.7'}]}]}, {'title': 'Week 40', 'categories': [{'measurements': [{'value': '57.5', 'groupId': 'OG000', 'lowerLimit': '49.9', 'upperLimit': '64.9'}, {'value': '74.0', 'groupId': 'OG001', 'lowerLimit': '67.0', 'upperLimit': '80.3'}]}]}, {'title': 'Week 44', 'categories': [{'measurements': [{'value': '56.4', 'groupId': 'OG000', 'lowerLimit': '48.8', 'upperLimit': '63.8'}, {'value': '71.3', 'groupId': 'OG001', 'lowerLimit': '64.1', 'upperLimit': '77.7'}]}]}, {'title': 'Week 48', 'categories': [{'measurements': [{'value': '60.9', 'groupId': 'OG000', 'lowerLimit': '53.3', 'upperLimit': '68.1'}, {'value': '75.7', 'groupId': 'OG001', 'lowerLimit': '68.8', 'upperLimit': '81.7'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'value': '53.6', 'groupId': 'OG000', 'lowerLimit': '46.0', 'upperLimit': '61.1'}, {'value': '72.9', 'groupId': 'OG001', 'lowerLimit': '65.8', 'upperLimit': '79.3'}]}]}, {'title': 'Week 56', 'categories': [{'measurements': [{'value': '51.4', 'groupId': 'OG000', 'lowerLimit': '43.8', 'upperLimit': '58.9'}, {'value': '70.2', 'groupId': 'OG001', 'lowerLimit': '62.9', 'upperLimit': '76.7'}]}]}, {'title': 'Week 60', 'categories': [{'measurements': [{'value': '55.3', 'groupId': 'OG000', 'lowerLimit': '47.7', 'upperLimit': '62.7'}, {'value': '69.1', 'groupId': 'OG001', 'lowerLimit': '61.8', 'upperLimit': '75.7'}]}]}, {'title': 'Week 64', 'categories': [{'measurements': [{'value': '48.6', 'groupId': 'OG000', 'lowerLimit': '41.1', 'upperLimit': '56.2'}, {'value': '69.6', 'groupId': 'OG001', 'lowerLimit': '62.4', 'upperLimit': '76.2'}]}]}, {'title': 'Week 68', 'categories': [{'measurements': [{'value': '47.5', 'groupId': 'OG000', 'lowerLimit': '40.0', 'upperLimit': '55.1'}, {'value': '66.9', 'groupId': 'OG001', 'lowerLimit': '59.5', 'upperLimit': '73.7'}]}]}, {'title': 'Week 72', 'categories': [{'measurements': [{'value': '45.8', 'groupId': 'OG000', 'lowerLimit': '38.4', 'upperLimit': '53.4'}, {'value': '66.9', 'groupId': 'OG001', 'lowerLimit': '59.5', 'upperLimit': '73.7'}]}]}, {'title': 'Week 76', 'categories': [{'measurements': [{'value': '50.3', 'groupId': 'OG000', 'lowerLimit': '42.7', 'upperLimit': '57.8'}, {'value': '63.0', 'groupId': 'OG001', 'lowerLimit': '55.5', 'upperLimit': '70.0'}]}]}, {'title': 'Week 80', 'categories': [{'measurements': [{'value': '45.8', 'groupId': 'OG000', 'lowerLimit': '38.4', 'upperLimit': '53.4'}, {'value': '65.7', 'groupId': 'OG001', 'lowerLimit': '58.3', 'upperLimit': '72.6'}]}]}, {'title': 'Week 84', 'categories': [{'measurements': [{'value': '40.2', 'groupId': 'OG000', 'lowerLimit': '33.0', 'upperLimit': '47.8'}, {'value': '63.0', 'groupId': 'OG001', 'lowerLimit': '55.5', 'upperLimit': '70.0'}]}]}, {'title': 'Week 88', 'categories': [{'measurements': [{'value': '48.0', 'groupId': 'OG000', 'lowerLimit': '40.5', 'upperLimit': '55.6'}, {'value': '64.1', 'groupId': 'OG001', 'lowerLimit': '56.6', 'upperLimit': '71.1'}]}]}, {'title': 'Week 92', 'categories': [{'measurements': [{'value': '44.7', 'groupId': 'OG000', 'lowerLimit': '37.3', 'upperLimit': '52.3'}, {'value': '59.1', 'groupId': 'OG001', 'lowerLimit': '51.6', 'upperLimit': '66.4'}]}]}, {'title': 'Week 96', 'categories': [{'measurements': [{'value': '41.3', 'groupId': 'OG000', 'lowerLimit': '34.0', 'upperLimit': '48.9'}, {'value': '61.9', 'groupId': 'OG001', 'lowerLimit': '54.4', 'upperLimit': '69.0'}]}]}, {'title': 'Week 100', 'categories': [{'measurements': [{'value': '40.8', 'groupId': 'OG000', 'lowerLimit': '33.5', 'upperLimit': '48.4'}, {'value': '56.9', 'groupId': 'OG001', 'lowerLimit': '49.4', 'upperLimit': '64.2'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-19.1', 'ciLowerLimit': '-28.9', 'ciUpperLimit': '-9.2', 'groupDescription': 'Intraretinal Fluid (IRF) at Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment Difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-16.1', 'ciLowerLimit': '-26.3', 'ciUpperLimit': '-5.7', 'groupDescription': 'Intraretinal Fluid (IRF) at Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment Difference'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Presence of Intraretinal Fluid (IRF) in the study eye was assessed by spectral domain optical coherence tomography (SD-OCT), angiography, and/or color fundus photography. Intraretinal fluid status assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Percentage of Patients With Presence of Subretinal Fluid (SRF) and/or Intraretinal Fluid (IRF) in the Study Eye at Each Post-baseline Visit', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '90.5', 'groupId': 'OG000', 'lowerLimit': '85.2', 'upperLimit': '94.4'}, {'value': '90.6', 'groupId': 'OG001', 'lowerLimit': '85.4', 'upperLimit': '94.4'}]}]}, {'title': 'Week 6', 'categories': [{'measurements': [{'value': '86.6', 'groupId': 'OG000', 'lowerLimit': '80.7', 'upperLimit': '91.2'}, {'value': '88.4', 'groupId': 'OG001', 'lowerLimit': '82.8', 'upperLimit': '92.7'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '87.2', 'groupId': 'OG000', 'lowerLimit': '81.3', 'upperLimit': '91.7'}, {'value': '85.6', 'groupId': 'OG001', 'lowerLimit': '79.7', 'upperLimit': '90.4'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '83.8', 'groupId': 'OG000', 'lowerLimit': '77.6', 'upperLimit': '88.9'}, {'value': '86.2', 'groupId': 'OG001', 'lowerLimit': '80.3', 'upperLimit': '90.9'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '76.0', 'groupId': 'OG000', 'lowerLimit': '69.0', 'upperLimit': '82.0'}, {'value': '84.0', 'groupId': 'OG001', 'lowerLimit': '77.8', 'upperLimit': '89.0'}]}]}, {'title': 'Week 18', 'categories': [{'measurements': [{'value': '78.2', 'groupId': 'OG000', 'lowerLimit': '71.4', 'upperLimit': '84.0'}, {'value': '81.2', 'groupId': 'OG001', 'lowerLimit': '74.8', 'upperLimit': '86.6'}]}]}, {'title': 'Week 20', 'categories': [{'measurements': [{'value': '73.2', 'groupId': 'OG000', 'lowerLimit': '66.1', 'upperLimit': '79.5'}, {'value': '79.6', 'groupId': 'OG001', 'lowerLimit': '72.9', 'upperLimit': '85.2'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'value': '70.4', 'groupId': 'OG000', 'lowerLimit': '63.1', 'upperLimit': '77.0'}, {'value': '82.3', 'groupId': 'OG001', 'lowerLimit': '76.0', 'upperLimit': '87.6'}]}]}, {'title': 'Week 28', 'categories': [{'measurements': [{'value': '68.7', 'groupId': 'OG000', 'lowerLimit': '61.4', 'upperLimit': '75.4'}, {'value': '75.1', 'groupId': 'OG001', 'lowerLimit': '68.2', 'upperLimit': '81.3'}]}]}, {'title': 'Week 32', 'categories': [{'measurements': [{'value': '68.7', 'groupId': 'OG000', 'lowerLimit': '61.4', 'upperLimit': '75.4'}, {'value': '76.8', 'groupId': 'OG001', 'lowerLimit': '70.0', 'upperLimit': '82.7'}]}]}, {'title': 'Week 36', 'categories': [{'measurements': [{'value': '73.7', 'groupId': 'OG000', 'lowerLimit': '66.7', 'upperLimit': '80.0'}, {'value': '72.4', 'groupId': 'OG001', 'lowerLimit': '65.3', 'upperLimit': '78.7'}]}]}, {'title': 'Week 40', 'categories': [{'measurements': [{'value': '58.1', 'groupId': 'OG000', 'lowerLimit': '50.5', 'upperLimit': '65.4'}, {'value': '74.0', 'groupId': 'OG001', 'lowerLimit': '67.0', 'upperLimit': '80.3'}]}]}, {'title': 'Week 44', 'categories': [{'measurements': [{'value': '57.0', 'groupId': 'OG000', 'lowerLimit': '49.4', 'upperLimit': '64.3'}, {'value': '71.3', 'groupId': 'OG001', 'lowerLimit': '64.1', 'upperLimit': '77.7'}]}]}, {'title': 'Week 48', 'categories': [{'measurements': [{'value': '61.5', 'groupId': 'OG000', 'lowerLimit': '53.9', 'upperLimit': '68.6'}, {'value': '75.7', 'groupId': 'OG001', 'lowerLimit': '68.8', 'upperLimit': '81.7'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'value': '54.2', 'groupId': 'OG000', 'lowerLimit': '46.6', 'upperLimit': '61.6'}, {'value': '72.9', 'groupId': 'OG001', 'lowerLimit': '65.8', 'upperLimit': '79.3'}]}]}, {'title': 'Week 56', 'categories': [{'measurements': [{'value': '52.0', 'groupId': 'OG000', 'lowerLimit': '44.4', 'upperLimit': '59.5'}, {'value': '70.2', 'groupId': 'OG001', 'lowerLimit': '62.9', 'upperLimit': '76.7'}]}]}, {'title': 'Week 60', 'categories': [{'measurements': [{'value': '55.3', 'groupId': 'OG000', 'lowerLimit': '47.7', 'upperLimit': '62.7'}, {'value': '69.1', 'groupId': 'OG001', 'lowerLimit': '61.8', 'upperLimit': '75.7'}]}]}, {'title': 'Week 64', 'categories': [{'measurements': [{'value': '49.2', 'groupId': 'OG000', 'lowerLimit': '41.6', 'upperLimit': '56.7'}, {'value': '69.6', 'groupId': 'OG001', 'lowerLimit': '62.4', 'upperLimit': '76.2'}]}]}, {'title': 'Week 68', 'categories': [{'measurements': [{'value': '48.0', 'groupId': 'OG000', 'lowerLimit': '40.5', 'upperLimit': '55.6'}, {'value': '68.0', 'groupId': 'OG001', 'lowerLimit': '60.6', 'upperLimit': '74.7'}]}]}, {'title': 'Week 72', 'categories': [{'measurements': [{'value': '46.9', 'groupId': 'OG000', 'lowerLimit': '39.4', 'upperLimit': '54.5'}, {'value': '66.9', 'groupId': 'OG001', 'lowerLimit': '59.5', 'upperLimit': '73.7'}]}]}, {'title': 'Week 76', 'categories': [{'measurements': [{'value': '50.8', 'groupId': 'OG000', 'lowerLimit': '43.3', 'upperLimit': '58.4'}, {'value': '63.0', 'groupId': 'OG001', 'lowerLimit': '55.5', 'upperLimit': '70.0'}]}]}, {'title': 'Week 80', 'categories': [{'measurements': [{'value': '46.4', 'groupId': 'OG000', 'lowerLimit': '38.9', 'upperLimit': '54.0'}, {'value': '65.7', 'groupId': 'OG001', 'lowerLimit': '58.3', 'upperLimit': '72.6'}]}]}, {'title': 'Week 84', 'categories': [{'measurements': [{'value': '40.8', 'groupId': 'OG000', 'lowerLimit': '33.5', 'upperLimit': '48.4'}, {'value': '63.0', 'groupId': 'OG001', 'lowerLimit': '55.5', 'upperLimit': '70.0'}]}]}, {'title': 'Week 88', 'categories': [{'measurements': [{'value': '48.6', 'groupId': 'OG000', 'lowerLimit': '41.1', 'upperLimit': '56.2'}, {'value': '64.1', 'groupId': 'OG001', 'lowerLimit': '56.6', 'upperLimit': '71.1'}]}]}, {'title': 'Week 92', 'categories': [{'measurements': [{'value': '45.3', 'groupId': 'OG000', 'lowerLimit': '37.8', 'upperLimit': '52.8'}, {'value': '59.1', 'groupId': 'OG001', 'lowerLimit': '51.6', 'upperLimit': '66.4'}]}]}, {'title': 'Week 96', 'categories': [{'measurements': [{'value': '41.3', 'groupId': 'OG000', 'lowerLimit': '34.0', 'upperLimit': '48.9'}, {'value': '61.9', 'groupId': 'OG001', 'lowerLimit': '54.4', 'upperLimit': '69.0'}]}]}, {'title': 'Week 100', 'categories': [{'measurements': [{'value': '40.8', 'groupId': 'OG000', 'lowerLimit': '33.5', 'upperLimit': '48.4'}, {'value': '56.9', 'groupId': 'OG001', 'lowerLimit': '49.4', 'upperLimit': '64.2'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-18.4', 'ciLowerLimit': '-28.5', 'ciUpperLimit': '-8.3', 'groupDescription': 'Subretinal Fluid (SRF) and/or Intraretinal Fluid (IRF) at Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment Difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-16.2', 'ciLowerLimit': '-26.4', 'ciUpperLimit': '-5.9', 'groupDescription': 'Subretinal Fluid (SRF) and/or Intraretinal Fluid (IRF) at Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Presence of Subretinal Fluid (SRF) and/or Intraretinal Fluid (IRF) in the study eye was assessed by spectral domain optical coherence tomography (SD-OCT), angiography, and/or color fundus photography. Fluid status (SRF and/or IRF) assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Presence of Leakage on Fluorescein Angiography (FA) at Weeks 52 and 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 52', 'categories': [{'measurements': [{'value': '54.7', 'groupId': 'OG000', 'lowerLimit': '47.2', 'upperLimit': '62.2'}, {'value': '79.4', 'groupId': 'OG001', 'lowerLimit': '72.8', 'upperLimit': '85.1'}]}]}, {'title': 'Week 100', 'categories': [{'measurements': [{'value': '46.9', 'groupId': 'OG000', 'lowerLimit': '39.4', 'upperLimit': '54.5'}, {'value': '65.6', 'groupId': 'OG001', 'lowerLimit': '58.1', 'upperLimit': '72.5'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-25.4', 'ciLowerLimit': '-34.4', 'ciUpperLimit': '-16.3', 'groupDescription': 'Fluorescein Angiography (FA) at Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-19.1', 'ciLowerLimit': '-29.1', 'ciUpperLimit': '-8.2', 'groupDescription': 'Fluorescein Angiography (FA) at Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 52, Week 100', 'description': 'Presence of leakage on Fluorescein Angiography as assessed by fluorescein angiography. Leakage on FA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With With >=2-step Improvement From Baseline in ETDRS Diabetic Retinopathy Severity Scale (ETDRS-DRSS) Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 28', 'categories': [{'measurements': [{'value': '25.0', 'groupId': 'OG000', 'lowerLimit': '18.8', 'upperLimit': '32.1'}, {'value': '20.9', 'groupId': 'OG001', 'lowerLimit': '15.2', 'upperLimit': '27.6'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'value': '29.0', 'groupId': 'OG000', 'lowerLimit': '22.4', 'upperLimit': '36.3'}, {'value': '27.7', 'groupId': 'OG001', 'lowerLimit': '21.2', 'upperLimit': '34.9'}]}]}, {'title': 'Week 76', 'categories': [{'measurements': [{'value': '30.1', 'groupId': 'OG000', 'lowerLimit': '23.4', 'upperLimit': '37.5'}, {'value': '30.5', 'groupId': 'OG001', 'lowerLimit': '23.8', 'upperLimit': '37.9'}]}]}, {'title': 'Week 100', 'categories': [{'measurements': [{'value': '35.8', 'groupId': 'OG000', 'lowerLimit': '28.7', 'upperLimit': '43.4'}, {'value': '31.1', 'groupId': 'OG001', 'lowerLimit': '24.3', 'upperLimit': '38.5'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.1', 'ciLowerLimit': '-5.6', 'ciUpperLimit': '7.8', 'groupDescription': '\\>=2-step improvement in ETDRS-DRSS at Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.5', 'ciLowerLimit': '-1.7', 'ciUpperLimit': '10.8', 'groupDescription': '\\>=2-step improvement in ETDRS-DRSS at Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The Diabetic Retinopathy Disease Severity Scale measures the 5 levels of diabetic retinopathy - none, mild, moderate, severe, and proliferative. DRSS assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With With >=3-step Improvement From Baseline in ETDRS Diabetic Retinopathy Severity Scale (ETDRS-DRSS) Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 28', 'categories': [{'measurements': [{'value': '13.1', 'groupId': 'OG000', 'lowerLimit': '8.5', 'upperLimit': '19.0'}, {'value': '11.3', 'groupId': 'OG001', 'lowerLimit': '7.0', 'upperLimit': '16.9'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'value': '14.8', 'groupId': 'OG000', 'lowerLimit': '9.9', 'upperLimit': '20.9'}, {'value': '15.3', 'groupId': 'OG001', 'lowerLimit': '10.3', 'upperLimit': '21.4'}]}]}, {'title': 'Week 76', 'categories': [{'measurements': [{'value': '18.8', 'groupId': 'OG000', 'lowerLimit': '13.3', 'upperLimit': '25.3'}, {'value': '15.3', 'groupId': 'OG001', 'lowerLimit': '10.3', 'upperLimit': '21.4'}]}]}, {'title': 'Week 100', 'categories': [{'measurements': [{'value': '21.0', 'groupId': 'OG000', 'lowerLimit': '15.3', 'upperLimit': '27.8'}, {'value': '16.9', 'groupId': 'OG001', 'lowerLimit': '11.7', 'upperLimit': '23.3'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.6', 'ciLowerLimit': '-7.1', 'ciUpperLimit': '5.7', 'groupDescription': '\\>=3-step improvement in ETDRS-DRSS at Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.9', 'ciLowerLimit': '-2.3', 'ciUpperLimit': '10.0', 'groupDescription': '\\>=3-step improvement in ETDRS-DRSS at Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The Diabetic Retinopathy Disease Severity Scale measures the 5 levels of diabetic retinopathy - none, mild, moderate, severe, and proliferative. DRSS assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With With >=2-step Worsening From Baseline in ETDRS Diabetic Retinopathy Severity Scale (ETDRS-DRSS) Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 28', 'categories': [{'measurements': [{'value': '2.3', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.7'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.1'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000', 'lowerLimit': '0.4', 'upperLimit': '4.9'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.1'}]}]}, {'title': 'Week 76', 'categories': [{'measurements': [{'value': '3.4', 'groupId': 'OG000', 'lowerLimit': '1.3', 'upperLimit': '7.3'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.1'}]}]}, {'title': 'Week 100', 'categories': [{'measurements': [{'value': '4.5', 'groupId': 'OG000', 'lowerLimit': '2.0', 'upperLimit': '8.8'}, {'value': '1.7', 'groupId': 'OG001', 'lowerLimit': '0.4', 'upperLimit': '4.9'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.1', 'ciLowerLimit': '-1.0', 'ciUpperLimit': '3.6', 'groupDescription': '\\>=2-step worsening in ETDRS-DRSS at Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.9', 'ciLowerLimit': '-0.5', 'ciUpperLimit': '6.9', 'groupDescription': '\\>=2-step worsening in ETDRS-DRSS at Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The Diabetic Retinopathy Disease Severity Scale was based on 7-field stereo color fundus photography and measured 5 levels of diabetic retinopathy - none, mild, moderate, severe, and proliferative. DRSS assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With With >=3-step Worsening From Baseline in ETDRS Diabetic Retinopathy Severity Scale (ETDRS-DRSS) Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 28', 'categories': [{'measurements': [{'value': '0.6', 'groupId': 'OG000', 'lowerLimit': '0.0', 'upperLimit': '3.1'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'value': '0.6', 'groupId': 'OG000', 'lowerLimit': '0.0', 'upperLimit': '3.1'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 76', 'categories': [{'measurements': [{'value': '0.6', 'groupId': 'OG000', 'lowerLimit': '0.0', 'upperLimit': '3.1'}, {'value': 'NA', 'comment': 'No participant satisfying the criteria of the response variable.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 100', 'categories': [{'measurements': [{'value': '0.6', 'groupId': 'OG000', 'lowerLimit': '0.0', 'upperLimit': '3.1'}, {'value': '1.1', 'groupId': 'OG001', 'lowerLimit': '0.1', 'upperLimit': '4.0'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.6', 'ciLowerLimit': '0.5', 'ciUpperLimit': '2.1', 'groupDescription': '\\>=3-step worsening in ETDRS-DRSS at Week 52', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.6', 'ciLowerLimit': '-2.6', 'ciUpperLimit': '1.3', 'groupDescription': '\\>=3-step worsening in ETDRS-DRSS at Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The Diabetic Retinopathy Disease Severity Scale was based on 7-field stereo color fundus photography and measured 5 levels of diabetic retinopathy - none, mild, moderate, severe, and proliferative. DRSS assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Progression to Proliferative Diabetic Retinopathy (PDR) as Assessed by ETDRS-DRSS Score of at Least 61 by Week 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '0.6', 'groupId': 'OG000', 'lowerLimit': '0.0', 'upperLimit': '3.4'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.4'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Clopper-Pearson exact method', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.0', 'ciLowerLimit': '-2.1', 'ciUpperLimit': '1.9', 'groupDescription': 'Proliferative diabetic retinopathy (PDR) of at least 61 by Week 100', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'Treatment difference'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 100', 'description': 'The Diabetic Retinopathy Disease Severity Scale was based on 7-field stereo color fundus photography and measured 5 levels of diabetic retinopathy - none, mild, moderate, severe, and proliferative. DRSS assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) - Last observation carried forward (LOCF)'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Ocular and Non-ocular Adverse Events (AEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Ocular adverse events', 'denoms': [{'units': 'Participants', 'counts': [{'value': '73', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}]}], 'categories': [{'title': 'Mild', 'measurements': [{'value': '52', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}]}, {'title': 'Moderate', 'measurements': [{'value': '15', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}]}, {'title': 'Severe', 'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}]}, {'title': 'Non-ocular adverse events', 'denoms': [{'units': 'Participants', 'counts': [{'value': '136', 'groupId': 'OG000'}, {'value': '141', 'groupId': 'OG001'}]}], 'categories': [{'title': 'Mild', 'measurements': [{'value': '52', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}]}, {'title': 'Moderate', 'measurements': [{'value': '51', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}]}, {'title': 'Severe', 'measurements': [{'value': '33', 'groupId': 'OG000'}, {'value': '40', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From randomization till 30 days safety follow-up, assessed up to 35 months.', 'description': 'The number of participants with ocular and non-ocular adverse events was was assessed by CTCAE and reported categorically: Mild, Moderate, Severe.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Set'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Composite Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '166', 'groupId': 'OG000'}, {'value': '168', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '5.7', 'spread': '11.91', 'groupId': 'OG000'}, {'value': '6.3', 'spread': '10.19', 'groupId': 'OG001'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '143', 'groupId': 'OG000'}, {'value': '150', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8.9', 'spread': '11.67', 'groupId': 'OG000'}, {'value': '6.7', 'spread': '12.12', 'groupId': 'OG001'}]}]}, {'title': 'Week 76', 'denoms': [{'units': 'Participants', 'counts': [{'value': '132', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '9.8', 'spread': '12.22', 'groupId': 'OG000'}, {'value': '7.6', 'spread': '11.81', 'groupId': 'OG001'}]}]}, {'title': 'Week 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '9.0', 'spread': '12.94', 'groupId': 'OG000'}, {'value': '6.2', 'spread': '14.13', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Observed. Data after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and were not included in this analysis.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - General Vision', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '166', 'groupId': 'OG000'}, {'value': '168', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '9.0', 'spread': '16.11', 'groupId': 'OG000'}, {'value': '10.2', 'spread': '15.63', 'groupId': 'OG001'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '143', 'groupId': 'OG000'}, {'value': '150', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '11.2', 'spread': '17.05', 'groupId': 'OG000'}, {'value': '10.5', 'spread': '17.14', 'groupId': 'OG001'}]}]}, {'title': 'Week 76', 'denoms': [{'units': 'Participants', 'counts': [{'value': '132', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '12.4', 'spread': '16.49', 'groupId': 'OG000'}, {'value': '12.0', 'spread': '16.40', 'groupId': 'OG001'}]}]}, {'title': 'Week 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '12.0', 'spread': '16.25', 'groupId': 'OG000'}, {'value': '10.1', 'spread': '18.73', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Observed. Data after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and were not included in this analysis.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Ocular Pain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '166', 'groupId': 'OG000'}, {'value': '168', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.1', 'spread': '19.52', 'groupId': 'OG000'}, {'value': '4.6', 'spread': '18.48', 'groupId': 'OG001'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '143', 'groupId': 'OG000'}, {'value': '150', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.6', 'spread': '18.75', 'groupId': 'OG000'}, {'value': '4.4', 'spread': '17.92', 'groupId': 'OG001'}]}]}, {'title': 'Week 76', 'denoms': [{'units': 'Participants', 'counts': [{'value': '132', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.2', 'spread': '16.95', 'groupId': 'OG000'}, {'value': '4.6', 'spread': '18.68', 'groupId': 'OG001'}]}]}, {'title': 'Week 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.3', 'spread': '16.60', 'groupId': 'OG000'}, {'value': '5.4', 'spread': '20.77', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Observed. Data after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and were not included in this analysis.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Near Activities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '165', 'groupId': 'OG000'}, {'value': '168', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.4', 'spread': '20.83', 'groupId': 'OG000'}, {'value': '6.3', 'spread': '18.42', 'groupId': 'OG001'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '143', 'groupId': 'OG000'}, {'value': '150', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '10.5', 'spread': '20.30', 'groupId': 'OG000'}, {'value': '9.3', 'spread': '19.57', 'groupId': 'OG001'}]}]}, {'title': 'Week 76', 'denoms': [{'units': 'Participants', 'counts': [{'value': '132', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '11.0', 'spread': '21.91', 'groupId': 'OG000'}, {'value': '9.2', 'spread': '18.76', 'groupId': 'OG001'}]}]}, {'title': 'Week 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '13.0', 'spread': '20.21', 'groupId': 'OG000'}, {'value': '7.3', 'spread': '21.71', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Observed. Data after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and were not included in this analysis.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Distance Activities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '166', 'groupId': 'OG000'}, {'value': '168', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.2', 'spread': '18.87', 'groupId': 'OG000'}, {'value': '5.6', 'spread': '15.78', 'groupId': 'OG001'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '143', 'groupId': 'OG000'}, {'value': '150', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '11.7', 'spread': '17.62', 'groupId': 'OG000'}, {'value': '8.2', 'spread': '17.12', 'groupId': 'OG001'}]}]}, {'title': 'Week 76', 'denoms': [{'units': 'Participants', 'counts': [{'value': '132', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '12.1', 'spread': '18.32', 'groupId': 'OG000'}, {'value': '8.1', 'spread': '16.71', 'groupId': 'OG001'}]}]}, {'title': 'Week 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '11.4', 'spread': '18.94', 'groupId': 'OG000'}, {'value': '6.6', 'spread': '19.07', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Observed. Data after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and were not included in this analysis.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Social Functioning', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '166', 'groupId': 'OG000'}, {'value': '168', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.3', 'spread': '15.82', 'groupId': 'OG000'}, {'value': '4.4', 'spread': '16.48', 'groupId': 'OG001'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '143', 'groupId': 'OG000'}, {'value': '150', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '7.1', 'spread': '16.22', 'groupId': 'OG000'}, {'value': '4.9', 'spread': '15.59', 'groupId': 'OG001'}]}]}, {'title': 'Week 76', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.3', 'spread': '16.65', 'groupId': 'OG000'}, {'value': '5.0', 'spread': '15.34', 'groupId': 'OG001'}]}]}, {'title': 'Week 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.1', 'spread': '16.78', 'groupId': 'OG000'}, {'value': '4.1', 'spread': '17.55', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Observed. Data after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and were not included in this analysis.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Mental Health', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '166', 'groupId': 'OG000'}, {'value': '168', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '7.9', 'spread': '19.53', 'groupId': 'OG000'}, {'value': '10.1', 'spread': '19.90', 'groupId': 'OG001'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '143', 'groupId': 'OG000'}, {'value': '150', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '12.6', 'spread': '22.42', 'groupId': 'OG000'}, {'value': '10.1', 'spread': '22.78', 'groupId': 'OG001'}]}]}, {'title': 'Week 76', 'denoms': [{'units': 'Participants', 'counts': [{'value': '132', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '13.5', 'spread': '21.02', 'groupId': 'OG000'}, {'value': '13.1', 'spread': '23.10', 'groupId': 'OG001'}]}]}, {'title': 'Week 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '13.3', 'spread': '20.91', 'groupId': 'OG000'}, {'value': '11.6', 'spread': '26.31', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Observed. Data after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and were not included in this analysis.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Role Difficulties', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '166', 'groupId': 'OG000'}, {'value': '168', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.9', 'spread': '25.13', 'groupId': 'OG000'}, {'value': '9.4', 'spread': '23.41', 'groupId': 'OG001'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '143', 'groupId': 'OG000'}, {'value': '150', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '12.2', 'spread': '24.76', 'groupId': 'OG000'}, {'value': '8.7', 'spread': '27.21', 'groupId': 'OG001'}]}]}, {'title': 'Week 76', 'denoms': [{'units': 'Participants', 'counts': [{'value': '132', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '14.0', 'spread': '28.44', 'groupId': 'OG000'}, {'value': '11.4', 'spread': '27.83', 'groupId': 'OG001'}]}]}, {'title': 'Week 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '12.3', 'spread': '28.14', 'groupId': 'OG000'}, {'value': '10.2', 'spread': '27.12', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Observed. Data after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and were not included in this analysis.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Dependency', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '166', 'groupId': 'OG000'}, {'value': '168', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '5.5', 'spread': '19.39', 'groupId': 'OG000'}, {'value': '3.6', 'spread': '20.34', 'groupId': 'OG001'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '143', 'groupId': 'OG000'}, {'value': '150', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '7.6', 'spread': '19.53', 'groupId': 'OG000'}, {'value': '3.9', 'spread': '22.49', 'groupId': 'OG001'}]}]}, {'title': 'Week 76', 'denoms': [{'units': 'Participants', 'counts': [{'value': '132', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '7.3', 'spread': '20.19', 'groupId': 'OG000'}, {'value': '5.6', 'spread': '23.24', 'groupId': 'OG001'}]}]}, {'title': 'Week 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.8', 'spread': '19.85', 'groupId': 'OG000'}, {'value': '2.9', 'spread': '24.79', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Observed. Data after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and were not included in this analysis.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Driving', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '94', 'groupId': 'OG000'}, {'value': '87', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.4', 'spread': '18.75', 'groupId': 'OG000'}, {'value': '4.8', 'spread': '12.24', 'groupId': 'OG001'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '84', 'groupId': 'OG000'}, {'value': '76', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.4', 'spread': '14.63', 'groupId': 'OG000'}, {'value': '4.2', 'spread': '12.81', 'groupId': 'OG001'}]}]}, {'title': 'Week 76', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8.9', 'spread': '15.95', 'groupId': 'OG000'}, {'value': '2.8', 'spread': '15.88', 'groupId': 'OG001'}]}]}, {'title': 'Week 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '78', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '5.4', 'spread': '15.81', 'groupId': 'OG000'}, {'value': '1.2', 'spread': '16.75', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Observed. Data after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and were not included in this analysis.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Color Vision', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '165', 'groupId': 'OG000'}, {'value': '166', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.5', 'spread': '15.10', 'groupId': 'OG000'}, {'value': '4.2', 'spread': '12.50', 'groupId': 'OG001'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '142', 'groupId': 'OG000'}, {'value': '147', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '5.8', 'spread': '15.08', 'groupId': 'OG000'}, {'value': '3.6', 'spread': '13.09', 'groupId': 'OG001'}]}]}, {'title': 'Week 76', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '141', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '5.2', 'spread': '15.73', 'groupId': 'OG000'}, {'value': '3.9', 'spread': '13.79', 'groupId': 'OG001'}]}]}, {'title': 'Week 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '129', 'groupId': 'OG000'}, {'value': '141', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.3', 'spread': '14.70', 'groupId': 'OG000'}, {'value': '3.2', 'spread': '15.48', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Observed. Data after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and were not included in this analysis.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Peripheral Vision', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '166', 'groupId': 'OG000'}, {'value': '167', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '5.3', 'spread': '18.83', 'groupId': 'OG000'}, {'value': '4.0', 'spread': '16.99', 'groupId': 'OG001'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '143', 'groupId': 'OG000'}, {'value': '149', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '7.2', 'spread': '18.68', 'groupId': 'OG000'}, {'value': '3.2', 'spread': '19.77', 'groupId': 'OG001'}]}]}, {'title': 'Week 76', 'denoms': [{'units': 'Participants', 'counts': [{'value': '132', 'groupId': 'OG000'}, {'value': '144', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '9.3', 'spread': '19.64', 'groupId': 'OG000'}, {'value': '4.3', 'spread': '17.82', 'groupId': 'OG001'}]}]}, {'title': 'Week 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '144', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8.5', 'spread': '19.33', 'groupId': 'OG000'}, {'value': '2.3', 'spread': '19.37', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Observed. Data after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and were not included in this analysis.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): General Health Rating', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '166', 'groupId': 'OG000'}, {'value': '168', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.9', 'spread': '18.66', 'groupId': 'OG000'}, {'value': '4.3', 'spread': '19.92', 'groupId': 'OG001'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '143', 'groupId': 'OG000'}, {'value': '150', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '5.8', 'spread': '22.34', 'groupId': 'OG000'}, {'value': '4.8', 'spread': '23.12', 'groupId': 'OG001'}]}]}, {'title': 'Week 76', 'denoms': [{'units': 'Participants', 'counts': [{'value': '132', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8.9', 'spread': '21.21', 'groupId': 'OG000'}, {'value': '7.1', 'spread': '22.57', 'groupId': 'OG001'}]}]}, {'title': 'Week 100', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '145', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.7', 'spread': '19.14', 'groupId': 'OG000'}, {'value': '5.7', 'spread': '21.80', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set - Observed. Data after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and were not included in this analysis.'}, {'type': 'SECONDARY', 'title': 'Systemic Brolucizumab Concentration', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '56.2', 'spread': '10.4', 'groupId': 'OG000'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '162', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.760', 'spread': '1.98', 'groupId': 'OG000'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '168', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'NA = not estimable: Below the limit of quantitation (\\<0.5 ng/mL)', 'groupId': 'OG000'}]}]}, {'title': 'Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '165', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'NA = not estimable: Below the limit of quantitation (\\<0.5 ng/mL)', 'groupId': 'OG000'}]}]}, {'title': 'Week 24 + 1 Day', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '41.5', 'spread': '80.5', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Up to Week 24', 'description': 'Serum samples were taken approximately 24 hours after the first dose and 24 hours after the treatment at Week 24 to confirm the systemic brolucizumab exposure in patients with visual impairment due to diabetic macular edema.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Set. Data after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and not included in the analysis.'}, {'type': 'SECONDARY', 'title': 'Distribution of Integrated Anti-Drug Antibody (ADA) Status in the Brolucizumab Arm', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'ADA negative or ADA positive with no boost', 'categories': [{'measurements': [{'value': '146', 'groupId': 'OG000'}]}]}, {'title': 'Induced or Boosted', 'categories': [{'measurements': [{'value': '27', 'groupId': 'OG000'}]}]}, {'title': 'Missing ADA at pre-dose or no post-dose ADA data', 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Week 100', 'description': 'Integrated ADA Status was categorized: ADA negative or ADA positive with no boost, Induced or Boosted, Missing ADA at pre-dose or no post-dose ADA data.\n\n* ADA negative: (a) ADA negative at all time points (pre-dose and post-dose), (b) ADA negative at pre-dose and no titer values above 40 at all other time points, (c) ADA titer of 40 at pre-dose but negative at all other time points.\n* ADA positive with no boost: ADA positive at pre-dose, post-dose titer values do not increase from pre-dose by more than 3-fold (1 dilution) at any time point.\n* Induced: ADA negative at pre-dose, post-dose titer value of 120 or more at any time point.\n* Boosted: ADA positive at pre-dose, post-dose titer values increase from pre-dose by more than 3-fold (1 dilution) at any time point.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Set. Data after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and not included in the analysis.'}, {'type': 'SECONDARY', 'title': 'Distribution of Integrated Anti-Drug Antibody (ADA) Status in the Brolucizumab Arm - Adjusted for Pre-existing ADA Status', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'ADA negative/ADA Negative or titer value of 40 at pre-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '84', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '53', 'groupId': 'OG000'}]}]}, {'title': 'ADA positive with no boost/ADA Positive at pre-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '110', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '93', 'groupId': 'OG000'}]}]}, {'title': 'Induced/ADA Negative at pre-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '64', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '14', 'groupId': 'OG000'}]}]}, {'title': 'Boosted/ADA Positive at pre-dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '110', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '13', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Week 100', 'description': 'Integrated ADA Status - adjusted for pre-existing ADA status was categorized: ADA negative, ADA positive with no boost, Induced, Boosted.\n\n* ADA negative: (a) ADA negative at all time points (pre-dose and post-dose), (b) ADA negative at pre-dose and no titer values above 40 at all other time points, (c) ADA titer of 40 at pre-dose but negative at all other time points.\n* ADA positive with no boost: ADA positive at pre-dose, post-dose titer values do not increase from pre-dose by more than 3-fold (1 dilution) at any time point.\n* Induced: ADA negative at pre-dose, post-dose titer value of 120 or more at any time point.\n* Boosted: ADA positive at pre-dose, post-dose titer values increase from pre-dose by more than 3-fold (1 dilution) at any time point.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Set. Data after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and not included in the analysis.'}, {'type': 'SECONDARY', 'title': 'Pre-existing ADA Status and Incidence of Adverse Event of Special Interest (AESI) in the Study Eye', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '64', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'categories': [{'title': 'At least 1 AESI', 'measurements': [{'value': '1', 'groupId': 'OG000'}]}, {'title': 'No AESI', 'measurements': [{'value': '63', 'groupId': 'OG000'}]}]}, {'title': 'Postive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '110', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'categories': [{'title': 'At least 1 AESI', 'measurements': [{'value': '5', 'groupId': 'OG000'}]}, {'title': 'No AESI', 'measurements': [{'value': '105', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Week 100', 'description': 'Pre-existing ADA status and incidence of Adverse Event of Special Interest (AESI) in the study eye was categorized: Negative, Positive.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Set. AEs started after the subject discontinued study treatment and started alternative diabetic macular edema (DME) treatment in the study eye were censored and not included in the analysis.'}, {'type': 'SECONDARY', 'title': 'Integrated ADA Status up to Week 100 and Incidence of Adverse Event of Special Interest (AESI) in the Study Eye.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'OG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'classes': [{'title': 'ADA-negative or no boost', 'denoms': [{'units': 'Participants', 'counts': [{'value': '146', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'categories': [{'title': 'At least 1 AESI', 'measurements': [{'value': '4', 'groupId': 'OG000'}]}, {'title': 'No AESI', 'measurements': [{'value': '142', 'groupId': 'OG000'}]}]}, {'title': 'Induced or boosted', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'categories': [{'title': 'At least 1 AESI', 'measurements': [{'value': '2', 'groupId': 'OG000'}]}, {'title': 'No AESI', 'measurements': [{'value': '25', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Week 100', 'description': 'Integrated ADA status up to Week 100 and incidence of Adverse Event of Special Interest (AESI) in the study eye was categorized: ADA-negative or no boost, Induced or boosted.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Set. AEs started after the subject discontinued study treatment and started alternative diabetic macular edema (DME) treatment in the study eye were censored and not included in the analysis.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'FG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'comment': 'All randomized treated patients were included in the Full Analysis Set (FAS) and Safety Analysis Set (SAF)', 'achievements': [{'groupId': 'FG000', 'numSubjects': '179'}, {'groupId': 'FG001', 'numSubjects': '181'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '143'}, {'groupId': 'FG001', 'numSubjects': '156'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '36'}, {'groupId': 'FG001', 'numSubjects': '25'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '4'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '13'}, {'groupId': 'FG001', 'numSubjects': '9'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '3'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '14'}, {'groupId': 'FG001', 'numSubjects': '7'}]}]}], 'recruitmentDetails': 'This study was conducted in 79 centers in 23 countries: Belgium (1), Bulgaria (3), Czech Republic (3), Denmark (2), Estonia (2), France (12), Germany (7), Hungary (5), India (5), Republic of Korea (6), Latvia (1), Lebanon (3), Lithuania (2), Malaysia (2), Norway (1), Poland (1), Russia (5), Singapore (2), Slovakia (5), Sweden (1), Switzerland (2), Taiwan (3), Turkey (5).'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '179', 'groupId': 'BG000'}, {'value': '181', 'groupId': 'BG001'}, {'value': '360', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule'}, {'id': 'BG001', 'title': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '62.3', 'spread': '10.55', 'groupId': 'BG000'}, {'value': '62.2', 'spread': '9.48', 'groupId': 'BG001'}, {'value': '62.2', 'spread': '10.01', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Age, Customized', 'classes': [{'title': '< 65 years', 'categories': [{'measurements': [{'value': '100', 'groupId': 'BG000'}, {'value': '102', 'groupId': 'BG001'}, {'value': '202', 'groupId': 'BG002'}]}]}, {'title': '>= 65 years', 'categories': [{'measurements': [{'value': '79', 'groupId': 'BG000'}, {'value': '79', 'groupId': 'BG001'}, {'value': '158', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '59', 'groupId': 'BG000'}, {'value': '66', 'groupId': 'BG001'}, {'value': '125', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '120', 'groupId': 'BG000'}, {'value': '115', 'groupId': 'BG001'}, {'value': '235', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '163', 'groupId': 'BG000'}, {'value': '170', 'groupId': 'BG001'}, {'value': '333', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '13', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '43', 'groupId': 'BG000'}, {'value': '48', 'groupId': 'BG001'}, {'value': '91', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '133', 'groupId': 'BG000'}, {'value': '132', 'groupId': 'BG001'}, {'value': '265', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2020-06-11', 'size': 648467, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2022-05-17T14:10', 'hasProtocol': True}, {'date': '2020-08-17', 'size': 484369, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2022-05-17T14:10', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 360}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2018-07-27', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-01', 'completionDateStruct': {'date': '2021-06-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-01-06', 'studyFirstSubmitDate': '2018-03-19', 'resultsFirstSubmitDate': '2022-05-17', 'studyFirstSubmitQcDate': '2018-03-27', 'lastUpdatePostDateStruct': {'date': '2025-01-07', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2023-04-04', 'studyFirstPostDateStruct': {'date': '2018-03-29', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2024-01-05', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-06-29', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52 for the Study Eye', 'timeFrame': 'Baseline, Week 52', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}], 'secondaryOutcomes': [{'measure': 'Average Mean Change From Baseline in BCVA Over the Period Week 40 Through Week 52 for the Study Eye', 'timeFrame': 'Baseline, period Week 40 through Week 52', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. For each participants, this endpoint was defined as the mean change from baseline to the average value over the period Week 40 through Week 52. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': '(Brolucizumab Treatment Arm Only): Percentage of Participants Maintained at q12w up to Week 52 and up to q12w/q16w up to Week 100.', 'timeFrame': 'Week 52, Week 100', 'description': 'The number of participants maintaining every 12 weeks (q12w) treatment status in the Brolucizumab arm was derived based on Kaplan-Meier estimates time-to-first q8w treatment need. Positive treatment status was defined as intravitreal treatment (IVT) injections per planned dosing regimen \\[every 12 weeks (q12w)\\].'}, {'measure': '(Brolucizumab Treatment Arm Only): Percentage of Participants Maintained at q12w up to Week 52 Within Those Patients That Qualified for q12w at Week 36', 'timeFrame': 'Week 36, Week 52', 'description': 'The number of participants maintaining every 12 weeks (q12w) treatment status in the Brolucizumab arm was derived based on Kaplan-Meier estimates time-to-first q8w treatment need. Positive treatment status was defined as intravitreal treatment (IVT) injections per planned dosing regimen \\[every 12 weeks (q12w)\\].'}, {'measure': '(Brolucizumab Treatment Arm Only): Percentage of Participants Maintained at q12w/q16w up to Week 100, Within Those Patients That Qualified for q12w at Week 36', 'timeFrame': 'Week 36, Week 100', 'description': 'Disease activity assessments (DAAs) were performed to identify q8w-need at pre-specified visits (Weeks 32, 36, 48, 60, 72 and every visit from Week 72 through Week 96). Weeks 32 and 36 were the two DAA visits of the initial q12w cycle after the loading phase of the brolucizumab arm. At Week 72 or Week 76 (if DAA/disease stability assessment was missed at Week 72), participants in the brolucizumab were evaluated for an additional 4-week dose regimen extension.\n\nThe number of participants maintaining every 12 weeks (q12w) treatment status in the Brolucizumab arm was derived based on Kaplan-Meier estimates time-to-first q8w treatment need. Positive treatment status was defined as intravitreal treatment (IVT) injections per planned dosing regimen \\[every 12 weeks (q12w)\\].'}, {'measure': '(Brolucizumab Treatment Arm Only): Percentage of Participants Maintained on q16w up to Week 100 Within the Patients on q12w at Week 68 and on q16w at Week 76', 'timeFrame': 'Week 68, Week 76, Week 100', 'description': 'Disease activity assessments (DAAs) were performed to identify q8w-need at pre-specified visits (Weeks 32, 36, 48, 60, 72 and every visit from Week 72 through Week 96). Weeks 32 and 36 were the two DAA visits of the initial q12w cycle after the loading phase of the brolucizumab arm. At Week 72 or Week 76 (if DAA/disease stability assessment was missed at Week 72), participants in the brolucizumab were evaluated for an additional 4-week dose regimen extension.\n\nThe number of participants maintaining every 12 weeks (q12w) treatment status in the Brolucizumab arm was derived based on Kaplan-Meier estimates time-to-first q8w treatment need. Positive treatment status was defined as intravitreal treatment (IVT) injections per planned dosing regimen \\[every 12 weeks (q12w)\\].'}, {'measure': '(Brolucizumab Treatment Arm Only): Percentage of Participants Re-assigned and Maintained on q12w up to Week 100 Within the Patients on q8w at Week 68 and on q12w at Week 80', 'timeFrame': 'Week 68, Week 80, Week 100', 'description': 'Disease activity assessments (DAAs) were performed to identify q8w-need at pre-specified visits (Weeks 32, 36, 48, 60, 72 and every visit from Week 72 through Week 96). Weeks 32 and 36 were the two DAA visits of the initial q12w cycle after the loading phase of the brolucizumab arm. At Week 72 or Week 76 (if DAA/disease stability assessment was missed at Week 72), participants in the brolucizumab were evaluated for an additional 4-week dose regimen extension.\n\nThe number of participants maintaining every 12 weeks (q12w) treatment status in the Brolucizumab arm was derived based on Kaplan-Meier estimates time-to-first q8w treatment need. Positive treatment status was defined as intravitreal treatment (IVT) injections per planned dosing regimen \\[every 12 weeks (q12w)\\].'}, {'measure': '(Brolucizumab Treatment Arm Only): Number of Participants With Injections Per Planned Dosing Regimen (Every 8, 12 or 16 Weeks)', 'timeFrame': 'Week 100', 'description': 'Reported categorically for the subjects who completed the study treatment period: every 8 weeks (q8w), Every 12 weeks (q12w), Every 16 weeks (q16w)'}, {'measure': 'Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Each Visit up to Week 100 for the Study Eye', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Average Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Over the Period Week 4 to Week 52/100 for the Study Eye', 'timeFrame': 'Baseline, period Week 4 through Week 52, period Week 4 through Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. For each participants, this endpoint was defined as the mean change from baseline to the average value over the periods: Week 4 through Week 52, Week 4 through Week 100. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Average Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Over the Period Week 20 to Week 52/100 and Week 28 to Week 52/100 for the Study Eye', 'timeFrame': 'Baseline, period Week 20 through Week 52, period Week 20 through Week 100, period Week 28 through Week 52, period Week 28 through Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. For each participants, this endpoint was defined as the mean change from baseline to the average value over the periods: Week 20 through Week 52, Week 20 through Week 100, Week 28 through Week 52, Week 28 through Week 100. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Average Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Over the Period Week 88 to 100 for the Study Eye', 'timeFrame': 'Baseline, period Week 88 through Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. For each participants, this endpoint was defined as the mean change from baseline to the average value over the period Week 88 through Week 100. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Percentage of Participants Who Gained >= 5 Letters in BCVA From Baseline or Reached BCVA >= 84 Letters at Each Post-baseline Visit for the Study Eye', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Percentage of Participants Who Gained >= 10 Letters in BCVA From Baseline or Reached BCVA >= 84 Letters at Each Post-baseline Visit for the Study Eye', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Percentage of Participants Who Gained >= 15 Letters in BCVA From Baseline or Reached BCVA >= 84 Letters at Each Post-baseline Visit for the Study Eye', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Percentage of Participants Who Lost >= 5 ETDRS Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Each Post-baseline Visit for the Study Eye', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Percentage of Participants Who Lost >= 10 ETDRS Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Each Post-baseline Visit for the Study Eye', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Percentage of Participants Who Lost >= 15 ETDRS Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Each Post-baseline Visit for the Study Eye', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Percentage of Participants With an Absolute Best Corrected Visual Acuity (BCVA) >= 73 ETDRS Letters at Each Post-baseline Visit for the Study Eye', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Mean Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit for the Study Eye', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'The thickness of the retina was measured using Spectral Domain (SD) optical coherence tomography (OCT) equipment (SD-OCT) and reported as a difference, in micrometers. a negative change from baseline indicates a reduction in thickness, whereas a positive change from baseline indicates an increase. An increase in thickness may indicate a progression of the underlying disease. CSFT assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Average Mean Change From Baseline in Central Subfield Thickness (CSFT) Over the Period Week 40 Through Week 52 / Week 88 Through Week 100 for the Study Eye', 'timeFrame': 'Baseline, period Week 40 through Week 52, period Week 88 through Week 100', 'description': 'The thickness of the retina was measured using Spectral Domain (SD) optical coherence tomography (OCT) equipment (SD-OCT) and reported as a difference, in micrometers. a negative change from baseline indicates a reduction in thickness, whereas a positive change from baseline indicates an increase. An increase in thickness may indicate a progression of the underlying disease. CSFT assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment. For each participants, this endpoint was derived as the average of the changes from Baseline to Weeks 40, 44, 48, 52. Then the same was derived over the period Week 88 through Week 100, considering the average of the changes from Baseline to Weeks 88, 92, 96, 100. This endpoint was only assessed in the year-2 analysis (Week 100).'}, {'measure': 'Average Mean Change From Baseline in CSFT Over the Period Week 4 to Week 52 / 100 for the Study Eye', 'timeFrame': 'Baseline, period Week 4 through Week 52, period Week 4 through Week 100', 'description': 'The thickness of the retina was measured using Spectral Domain (SD) optical coherence tomography (OCT) equipment (SD-OCT) and reported as a difference, in micrometers. a negative change from baseline indicates a reduction in thickness, whereas a positive change from baseline indicates an increase. An increase in thickness may indicate a progression of the underlying disease. CSFT assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Percentage of Participants With Normal CSFT Thickness (<280 Micrometers) at Each Post-baseline Visit for the Study Eye', 'timeFrame': 'Baseline, Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'The thickness of the retina was measured using Spectral Domain (SD) optical coherence tomography (OCT) equipment (SD-OCT) and reported as a difference, in micrometers. CSFT assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Percentage of Patients With Presence of Subretinal Fluid (SRF) in the Study Eye at Each Post-baseline Visit', 'timeFrame': 'Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Presence of Subretinal Fluid (SRF) in the study eye was assessed by spectral domain optical coherence tomography (SD-OCT), angiography, and/or color fundus photography. Subretinal fluid status assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Percentage of Patients With Presence of Intraretinal Fluid (IRF) in the Study Eye at Each Post-baseline Visit', 'timeFrame': 'Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Presence of Intraretinal Fluid (IRF) in the study eye was assessed by spectral domain optical coherence tomography (SD-OCT), angiography, and/or color fundus photography. Intraretinal fluid status assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Percentage of Patients With Presence of Subretinal Fluid (SRF) and/or Intraretinal Fluid (IRF) in the Study Eye at Each Post-baseline Visit', 'timeFrame': 'Week 4, Week 6, Week 8, Week 12, Week 16, Week 18, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72, Week 76, Week 80, Week 84, Week 88, Week 92, Week 96, Week 100', 'description': 'Presence of Subretinal Fluid (SRF) and/or Intraretinal Fluid (IRF) in the study eye was assessed by spectral domain optical coherence tomography (SD-OCT), angiography, and/or color fundus photography. Fluid status (SRF and/or IRF) assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Percentage of Participants With Presence of Leakage on Fluorescein Angiography (FA) at Weeks 52 and 100', 'timeFrame': 'Week 52, Week 100', 'description': 'Presence of leakage on Fluorescein Angiography as assessed by fluorescein angiography. Leakage on FA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Percentage of Participants With With >=2-step Improvement From Baseline in ETDRS Diabetic Retinopathy Severity Scale (ETDRS-DRSS) Score', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The Diabetic Retinopathy Disease Severity Scale measures the 5 levels of diabetic retinopathy - none, mild, moderate, severe, and proliferative. DRSS assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Percentage of Participants With With >=3-step Improvement From Baseline in ETDRS Diabetic Retinopathy Severity Scale (ETDRS-DRSS) Score', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The Diabetic Retinopathy Disease Severity Scale measures the 5 levels of diabetic retinopathy - none, mild, moderate, severe, and proliferative. DRSS assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Percentage of Participants With With >=2-step Worsening From Baseline in ETDRS Diabetic Retinopathy Severity Scale (ETDRS-DRSS) Score', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The Diabetic Retinopathy Disease Severity Scale was based on 7-field stereo color fundus photography and measured 5 levels of diabetic retinopathy - none, mild, moderate, severe, and proliferative. DRSS assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Percentage of Participants With With >=3-step Worsening From Baseline in ETDRS Diabetic Retinopathy Severity Scale (ETDRS-DRSS) Score', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The Diabetic Retinopathy Disease Severity Scale was based on 7-field stereo color fundus photography and measured 5 levels of diabetic retinopathy - none, mild, moderate, severe, and proliferative. DRSS assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Percentage of Participants With Progression to Proliferative Diabetic Retinopathy (PDR) as Assessed by ETDRS-DRSS Score of at Least 61 by Week 100', 'timeFrame': 'Week 100', 'description': 'The Diabetic Retinopathy Disease Severity Scale was based on 7-field stereo color fundus photography and measured 5 levels of diabetic retinopathy - none, mild, moderate, severe, and proliferative. DRSS assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.'}, {'measure': 'Number of Participants With Ocular and Non-ocular Adverse Events (AEs)', 'timeFrame': 'From randomization till 30 days safety follow-up, assessed up to 35 months.', 'description': 'The number of participants with ocular and non-ocular adverse events was was assessed by CTCAE and reported categorically: Mild, Moderate, Severe.'}, {'measure': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Composite Score', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.'}, {'measure': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - General Vision', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.'}, {'measure': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Ocular Pain', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.'}, {'measure': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Near Activities', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.'}, {'measure': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Distance Activities', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.'}, {'measure': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Social Functioning', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.'}, {'measure': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Mental Health', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.'}, {'measure': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Role Difficulties', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.'}, {'measure': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Dependency', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.'}, {'measure': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Driving', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.'}, {'measure': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Color Vision', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.'}, {'measure': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): Subscale Score - Peripheral Vision', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.'}, {'measure': 'Change From Baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25): General Health Rating', 'timeFrame': 'Baseline, Week 28, Week 52, Week 76, Week 100', 'description': 'The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicated the best possible response. The composite score and score of each construct also ranged from 0 to 100 as they were calculated as total scores divided by the number of questions. The higher the values of total scores represented better outcome.'}, {'measure': 'Systemic Brolucizumab Concentration', 'timeFrame': 'Up to Week 24', 'description': 'Serum samples were taken approximately 24 hours after the first dose and 24 hours after the treatment at Week 24 to confirm the systemic brolucizumab exposure in patients with visual impairment due to diabetic macular edema.'}, {'measure': 'Distribution of Integrated Anti-Drug Antibody (ADA) Status in the Brolucizumab Arm', 'timeFrame': 'Up to Week 100', 'description': 'Integrated ADA Status was categorized: ADA negative or ADA positive with no boost, Induced or Boosted, Missing ADA at pre-dose or no post-dose ADA data.\n\n* ADA negative: (a) ADA negative at all time points (pre-dose and post-dose), (b) ADA negative at pre-dose and no titer values above 40 at all other time points, (c) ADA titer of 40 at pre-dose but negative at all other time points.\n* ADA positive with no boost: ADA positive at pre-dose, post-dose titer values do not increase from pre-dose by more than 3-fold (1 dilution) at any time point.\n* Induced: ADA negative at pre-dose, post-dose titer value of 120 or more at any time point.\n* Boosted: ADA positive at pre-dose, post-dose titer values increase from pre-dose by more than 3-fold (1 dilution) at any time point.'}, {'measure': 'Distribution of Integrated Anti-Drug Antibody (ADA) Status in the Brolucizumab Arm - Adjusted for Pre-existing ADA Status', 'timeFrame': 'Up to Week 100', 'description': 'Integrated ADA Status - adjusted for pre-existing ADA status was categorized: ADA negative, ADA positive with no boost, Induced, Boosted.\n\n* ADA negative: (a) ADA negative at all time points (pre-dose and post-dose), (b) ADA negative at pre-dose and no titer values above 40 at all other time points, (c) ADA titer of 40 at pre-dose but negative at all other time points.\n* ADA positive with no boost: ADA positive at pre-dose, post-dose titer values do not increase from pre-dose by more than 3-fold (1 dilution) at any time point.\n* Induced: ADA negative at pre-dose, post-dose titer value of 120 or more at any time point.\n* Boosted: ADA positive at pre-dose, post-dose titer values increase from pre-dose by more than 3-fold (1 dilution) at any time point.'}, {'measure': 'Pre-existing ADA Status and Incidence of Adverse Event of Special Interest (AESI) in the Study Eye', 'timeFrame': 'Up to Week 100', 'description': 'Pre-existing ADA status and incidence of Adverse Event of Special Interest (AESI) in the study eye was categorized: Negative, Positive.'}, {'measure': 'Integrated ADA Status up to Week 100 and Incidence of Adverse Event of Special Interest (AESI) in the Study Eye.', 'timeFrame': 'Up to Week 100', 'description': 'Integrated ADA status up to Week 100 and incidence of Adverse Event of Special Interest (AESI) in the study eye was categorized: ADA-negative or no boost, Induced or boosted.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Diabetic Macular Edema', 'intravitreal injection', 'brolucizumab', 'aflibercept', 'double-masked'], 'conditions': ['Diabetic Macular Edema']}, 'descriptionModule': {'briefSummary': 'This was a Phase III, randomized, double-masked, multi-center, active-controlled, two-arm study designed to evaluate the efficacy and safety of brolucizumab 6 mg compared to the active control, aflibercept 2 mg used per authorized label, in subjects with visual impairment due to diabetic macular edema (DME).', 'detailedDescription': 'The study included a screening period of up to 2 weeks to assess eligibility, followed by a double-masked treatment period (Day 1 to Week 96). The baseline visit was defined as Day 1/Visit 1, and end of treatment visit as Visit 27 (Week 96). After the last treatment visit, there was a post-treatment follow-up period from Week 96 to Week 100 and an exit visit at Week 100. Subjects were assigned to one of two treatment arms in a 1:1 ratio: brolucizumab 6 mg/0.05 mL (5 loading doses each administered every 6 weeks (q6w) during loading phase then q12w/q8w during maintenance phase with an option to extend treatment interval by 4 weeks during the second year) or aflibercept 2 mg/0.05 mL (5 loading doses each administered every 4 weeks (q4w) during loading phase then q8w during maintenance phase).\n\nDisease activity assessments (DAAs) were conducted by the masked investigator for both treatment arms at Week 32 and Week 36, i.e., 8 and 12 weeks after the end of the loading phase for subjects receiving brolucizumab, and at Week 48, Week 60 and Week 72 (i.e., every 12 weeks). In the brolucizumab arm, subjects who qualified for q12w during this initial q12w interval continued on a q12w treatment frequency unless disease activity was identified at any of the subsequent DAA visits, in which case subjects were switched to a q8w treatment interval until Week 72.\n\nA one-time disease stability assessment was performed by the masked investigator at Week 72 in both treatment arms with the purpose of evaluating the potential for treatment interval extension by 4 weeks. The subjects in the brolucizumab arm who demonstrated disease stability in the one-time assessment at Week 72 under their current assigned treatment regimen (q12w or q8w) were considered for treatment interval extension. To evaluate the adequacy of the individualized q8w, q12w or q16w treatment intervals in the brolucizumab arm, DAAs were performed at every visit from Week 72 up to and including Week 96 (i.e., every 4 weeks) and subjects had their treatment interval modified accordingly. If after Week 72 disease activity had been identified by the masked investigator at a scheduled treatment visit (according to the subject specific treatment schedule q12w or q16w) the subject was assigned to q8w treatment schedule.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Key Inclusion Criteria:\n\nGeneral\n\n* Patients must give written informed consent before any study related assessments are performed\n* Patients with type 1 or type 2 diabetes mellitus and HbA1c of =\\< 10% at screening\n* Medication for the management of diabetes must have been stable within 3 months prior to randomization and is expected to remain stable during the course of the study\n\nStudy Eye\n\n* Visual impairment due to DME with:\n\n 1. BCVA score between 78 and 23 letters, inclusive, using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts at a testing distance of 4 meters (approximate Snellen equivalent of 20/32 to 20/320), at screening and baseline\n 2. DME involving the center of the macula, with central subfield retinal thickness (measured from RPE to ILM inclusively) of \\>= 320 micrometers (μm) on SD-OCT at screening If both eyes are eligible, the eye with the worse visual acuity will be selected for study eye. However, the investigator may select the eye with better visual acuity, based on medical reasons or local ethical requirements.\n\n Key Exclusion Criteria:\n* Previous treatment with any anti-VEGF drugs or investigational drugs in the study eye\n* Active proliferative diabetic retinopathy in the study eye as per the investigator\n* Concomitant conditions or ocular disorders in the study eye at screening or baseline which could, in the opinion of the investigator, prevent response to study treatment or may confound interpretation of study results, compromise visual acuity or require medical or surgical intervention during the first 12-month study period (e.g., cataract, vitreous hemorrhage, retinal vascular occlusion, retinal detachment, macular hole, or choroidal neovascularization of any cause)\n* Any active intraocular or periocular infection or active intraocular inflammation (e.g., infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis) in study eye at screening or baseline\n* Structural damage of the fovea in the study eye at screening likely to preclude improvement in visual acuity following the resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s), epiretinal membrane involving fovea or organized hard exudate plaques\n* Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) \\> 25 millimeters mercury (mmHg) on medication or according to investigator's judgment, at screening or baseline\n* Neovascularization of the iris in the study eye at screening or baseline\n* Evidence of vitreomacular traction in the study eye at screening or baseline which, in the opinion of the investigator, affect visual acuity"}, 'identificationModule': {'nctId': 'NCT03481660', 'acronym': 'KITE', 'briefTitle': 'A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema', 'organization': {'class': 'INDUSTRY', 'fullName': 'Novartis'}, 'officialTitle': 'A Two-Year, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema', 'orgStudyIdInfo': {'id': 'CRTH258B2302'}, 'secondaryIdInfos': [{'id': '2017-003960-11', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Brolucizumab 6 mg', 'description': 'Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule', 'interventionNames': ['Drug: Brolucizumab']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Aflibercept 2 mg', 'description': 'Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks', 'interventionNames': ['Drug: Aflibercept']}], 'interventions': [{'name': 'Brolucizumab', 'type': 'DRUG', 'otherNames': ['RTH258, ESBA1008'], 'description': 'Intravitreal injection', 'armGroupLabels': ['Brolucizumab 6 mg']}, {'name': 'Aflibercept', 'type': 'DRUG', 'otherNames': ['Eylea'], 'description': 'Intravitreal injection', 'armGroupLabels': ['Aflibercept 2 mg']}]}, 'contactsLocationsModule': {'locations': [{'zip': '3570', 'city': 'Alken', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.87553, 'lon': 5.30558}}, {'zip': '1606', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1784', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '9000', 'city': 'Varna', 'country': 'Bulgaria', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.21912, 'lon': 27.91024}}, {'zip': '500 05', 'city': 'Hradec Králové', 'state': 'CZE', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.20923, 'lon': 15.83277}}, {'zip': '100 34', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '12808', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '9000', 'city': 'Aalborg', 'country': 'Denmark', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 57.048, 'lon': 9.9187}}, {'zip': '4000', 'city': 'Roskilde', 'country': 'Denmark', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.64152, 'lon': 12.08035}}, {'zip': '11412', 'city': 'Tallinn', 'country': 'Estonia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 59.43696, 'lon': 24.75353}}, {'zip': '51014', 'city': 'Tartu', 'country': 'Estonia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 58.38062, 'lon': 26.72509}}, {'zip': '69317', 'city': 'Lyon', 'state': 'Rhone', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '93009', 'city': 'Bobigny', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.90982, 'lon': 2.45012}}, {'zip': '33000', 'city': 'Bordeaux', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'zip': '94000', 'city': 'Créteil', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.79266, 'lon': 2.46569}}, {'zip': '21034', 'city': 'Dijon', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}, {'zip': '69275', 'city': 'Lyon', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': 'F 13008', 'city': 'Marseille', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'zip': '82000', 'city': 'Montauban', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.01759, 'lon': 1.3542}}, {'zip': '44093', 'city': 'Nantes', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'zip': '75010', 'city': 'Paris', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75015', 'city': 'Paris', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '76100', 'city': 'Rouen', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.44313, 'lon': 1.09932}}, {'zip': '10713', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '40212', 'city': 'Düsseldorf', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.22172, 'lon': 6.77616}}, {'zip': '79106', 'city': 'Freiburg im Breisgau', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.9959, 'lon': 7.85222}}, {'zip': '37075', 'city': 'Göttingen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.53443, 'lon': 9.93228}}, {'zip': '04103', 'city': 'Leipzig', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'zip': '48145', 'city': 'Münster', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.96236, 'lon': 7.62571}}, {'zip': '89075', 'city': 'Ulm', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.39841, 'lon': 9.99155}}, {'zip': 'H-1083', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '4032', 'city': 'Debrecen', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'zip': '4400', 'city': 'Nyíregyháza', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.95539, 'lon': 21.71671}}, {'zip': 'H 6725', 'city': 'Szeged', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.253, 'lon': 20.14824}}, {'zip': 'H-9700', 'city': 'Szombathely', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.23088, 'lon': 16.62155}}, {'zip': '600006', 'city': 'Chennai', 'state': 'Tamil Nadu', 'country': 'India', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 13.08784, 'lon': 80.27847}}, {'zip': '641014', 'city': 'Coimbatore', 'state': 'Tamil Nadu', 'country': 'India', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 11.00555, 'lon': 76.96612}}, {'zip': '500 034', 'city': 'Hyderabad', 'state': 'Telangana', 'country': 'India', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 17.38405, 'lon': 78.45636}}, {'zip': '160012', 'city': 'Chandigarh', 'country': 'India', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 30.73629, 'lon': 76.7884}}, {'zip': '110029', 'city': 'New Delhi', 'country': 'India', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 28.62137, 'lon': 77.2148}}, {'zip': 'LV 1002', 'city': 'Riga', 'country': 'Latvia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 56.946, 'lon': 24.10589}}, {'zip': '116-5311', 'city': 'Beirut', 'country': 'Lebanon', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 33.89332, 'lon': 35.50157}}, {'zip': '70-933', 'city': 'Beirut', 'country': 'Lebanon', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 33.89332, 'lon': 35.50157}}, {'zip': '166830', 'city': 'El Achrafiyé', 'country': 'Lebanon', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 33.88533, 'lon': 35.51961}}, {'zip': 'LT 50161', 'city': 'Kaunas', 'state': 'LTU', 'country': 'Lithuania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.90156, 'lon': 23.90909}}, {'zip': 'LT-08661', 'city': 'Vilnius', 'country': 'Lithuania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'zip': '46150', 'city': 'Petaling Jaya', 'state': 'Selangor', 'country': 'Malaysia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 3.10726, 'lon': 101.60671}}, {'zip': '40000', 'city': 'Shah Alam', 'state': 'Selangor', 'country': 'Malaysia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 3.08507, 'lon': 101.53281}}, {'zip': 'NO-0407', 'city': 'Oslo', 'country': 'Norway', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 59.91273, 'lon': 10.74609}}, {'zip': '80 809', 'city': 'Gdansk', 'country': 'Poland', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.35227, 'lon': 18.64912}}, {'zip': '428028', 'city': 'Cheboksary', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 56.13218, 'lon': 47.246}}, {'zip': '420066', 'city': "Kazan'", 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.78874, 'lon': 49.12214}}, {'zip': '119021', 'city': 'Moscow', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '127486', 'city': 'Moscow', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '620109', 'city': 'Yekaterinburg', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 56.85733, 'lon': 60.61529}}, {'zip': '168751', 'city': 'Singapore', 'country': 'Singapore', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'zip': 'S308433', 'city': 'Singapore', 'country': 'Singapore', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'zip': '975 17', 'city': 'Banská Bystrica', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.73947, 'lon': 19.14932}}, {'zip': '82606', 'city': 'Bratislava', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.14816, 'lon': 17.10674}}, {'zip': '83301', 'city': 'Bratislava', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.14816, 'lon': 17.10674}}, {'zip': '05845', 'city': 'Poprad', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.06144, 'lon': 20.29798}}, {'zip': '91101', 'city': 'Trenčín', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.89452, 'lon': 18.04436}}, {'zip': '13620', 'city': 'Bundang Gu', 'state': 'Gyeonggi-do', 'country': 'South Korea', 'facility': 'Novartis Investigative Site'}, {'zip': '49241', 'city': 'Busan', 'country': 'South Korea', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 35.10168, 'lon': 129.03004}}, {'zip': '02841', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '05505', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '06351', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '07301', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '701 85', 'city': 'Örebro', 'country': 'Sweden', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 59.27412, 'lon': 15.2066}}, {'zip': '3007', 'city': 'Bern', 'country': 'Switzerland', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.94809, 'lon': 7.44744}}, {'zip': '8063', 'city': 'Zurich', 'country': 'Switzerland', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.36667, 'lon': 8.55}}, {'zip': '50006', 'city': 'Changhua', 'country': 'Taiwan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 24.0692, 'lon': 120.5512}}, {'zip': '40447', 'city': 'Taichung', 'country': 'Taiwan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'zip': '33305', 'city': 'Taoyuan District', 'country': 'Taiwan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 24.9896, 'lon': 121.3187}}, {'zip': '06230', 'city': 'Ankara', 'country': 'Turkey (Türkiye)', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'zip': '27310', 'city': 'Gaziantep', 'country': 'Turkey (Türkiye)', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 37.05944, 'lon': 37.3825}}, {'zip': '35340', 'city': 'Izmir', 'country': 'Turkey (Türkiye)', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 38.41273, 'lon': 27.13838}}, {'zip': '41380', 'city': 'Kocaeli', 'country': 'Turkey (Türkiye)', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 39.62497, 'lon': 27.51145}}], 'overallOfficials': [{'name': 'Novartis Pharmaceuticals', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Novartis Pharmaceuticals'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.\n\nThis trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Novartis Pharmaceuticals', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}